University of Rhode Island

DigitalCommons@URI
Open Access Dissertations
2018

STIMULI-RESPONSIVE BIOMATERIALS FOR DRUG DELIVERY TO
IMPROVE CANCER IMMUNOTHERAPY AND CHRONIC WOUND
HEALING
Anita E. Tolouei
University of Rhode Island, anita.tolouei@gmail.com

Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss

Recommended Citation
Tolouei, Anita E., "STIMULI-RESPONSIVE BIOMATERIALS FOR DRUG DELIVERY TO IMPROVE CANCER
IMMUNOTHERAPY AND CHRONIC WOUND HEALING" (2018). Open Access Dissertations. Paper 798.
https://digitalcommons.uri.edu/oa_diss/798

This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for
inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.

STIMULI-RESPONSIVE BIOMATERIALS FOR DRUG
DELIVERY TO IMPROVE CANCER IMMUNOTHERAPY AND
CHRONIC WOUND HEALING
BY
ANITA E. TOLOUEI

A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY
IN
CHEMICAL ENGINEERING

UNIVERSITY OF RHODE ISLAND
2018

DOCTOR OF PHILOSOPHY DISSERTATION

OF

ANITA E. TOLOUEI

APPROVED:

Dissertation Committee:

Major Professor

Stephen M. Kennedy

Samantha A. Meenach

Niall J. Howlett

Nasser H. Zawia
DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2018

ABSTRACT
Sequential delivery of biomolecules is very important as many biologics
underlying injury and disease follow an orderly and sequenced series of events. Here we
developed and introduced for the first time a dual compartment biomaterial system with
an outer compartment made of gelatin and inner compartment that is a ferrogel which can
be magnetically stimulated in order to provide on-demand, sequential delivery of multiple
bio-instructive payload. We studied the potential application of this dual-compartment
biomaterial system in different therapeutic contexts that may benefit from on-demand
sequential deliveries, such as in cancer immunotherapy and in chronic wound healing.
Chronic wounds can be a result of arrest in the inflammation phase of healing.
Although inflammation critically initiates repair and helps clear infections, a prolonged
inflammatory reaction can cause considerable harm to the injury site. After an
appropriate duration of inflammation, this inflammatory response can be shifted to a
more pro-healing response through the delivery of cytokines like interleukin 4 (IL-4) and
interleukin 10 (IL-10). These anti-inflammatory cytokines alter the phenotype of
macrophages from pro-inflammatory (M1) to anti-inflammatory (M2), suggesting a
potentially powerful drug delivery strategy if these cytokines can be delivered in a
delayed manner. We hypothesize that the transition of macrophage phenotype from proinflammatory (M1) to anti-inflammatory (M2) can be controlled through sequenced
delivery of interferon gamma (IFN-γ), followed by IL-4 and/or IL-10. The goal of this
research was to develop a wound-healing hydrogel system that initially delivers proinflammatory IFN-γ, followed by magnetically triggered delivery of pro-healing (antiinflammatory) IL-4 and/or IL-10. Our biomaterial system was composed of two-

compartments: (1) a porous gelatin outer compartment designed to recruit macrophages
and establish an initial pro-inflammatory (M1) phenotype, and (2) a magnetically
responsive alginate inner compartment which was designed to deliver IL-4 and/or IL-10
when magnetically triggered to shift the response to anti-inflammatory by promoting
(M2) phenotype. We showed that we can have fast release of IFNg (Promotes M1
phenotype) and MCP-1 (recruits macrophages) initially from the outer compartment
while holding on to IL4 and IL10 that is loaded in the ferrogel and have them burst
release when applying the magnetic field.
Biomaterial-based cancer immunotherapy strategies require materials capable of
recruiting dendritic cells (DCs) and reprogramming them with cancer antigen and danger
signal. This strategy requires the implantation of a biomaterial that is loaded with DC
recruitment factors, danger signals, and cancer antigen. This co-delivery of danger signal
and antigen results in DC activation and homing of cancer-antigen-presenting DCs to the
lymph nodes, subsequently triggering an anti-tumor immune response from the host.
However, danger signals and antigen diffuse out of the biomaterial while DCs are being
actively recruited to the biomaterial. This may result in lower concentrations of these
necessary reprogramming agents by the time DCs are recruited and consequently, lower
quantities of activated DCs, and a reduced anti-tumor immune response. It is possible that
sequential release of DC recruitment and reprogramming factors will enhance the number
of reprogrammed DCs over simultaneous release, leading to improved anti-cancer
immune responses. In order to test this, a material system with unique delivery
capabilities must be developed. Therefore, we designed a biomaterial system capable of
first recruiting DCs by initially releasing DC recruitment factors from outer compartment.

This biomaterial can deliver reprogramming agents (i.e., cancer antigen) when
magnetically stimulated only after a substantial population of DCs has been recruited.
The results showed that we were able to deliver GM-CSF (DC recruitment factor)
initially from the outer compartment followed by delivering HSP27 (model cancer
antigen) when stimulated in the magnetic field
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PREFACE
This dissertation is presented in manuscript format in accordance with University
of Rhode Island Graduate School Guidelines. There are five chapters included in this
dissertation. The first chapter is an introduction and motivation to this work, including a
detailing of the problems being address, hypotheses, and goals of the work. The second
chapter is review of the literature on Magnetically responsive drug delivery depots as part
of an invited review in preparation to be submitted to Acta Biomaterialia. The third
chapter is published in Advanced Healthcare Materials journal with title of “A
Magnetically Responsive Biomaterial System for Flexibly Regulating the Duration
between Pro- and Anti-Inflammatory Cytokine Deliveries”, the Authors are listed in
order as Anita E. Tolouei, Nihan Dulger, Rosa Ghatee and Stephen Kennedy. The fourth
chapter is a paper in preparation to submit to ACS Biomaterials Science and Engineering
titled as “Magnetically Responsive Biomaterial System Enables On-demand, Sequential
Delivery of Biomolecules for a Variety of Biomedical Applications” and the authors are
listed as following Anita E. Tolouei, Tania T. Emi, Zahra M. Madani and Stephen
Kennedy. The final chapter is a detailing of the primary conclusions of this dissertation
and perspectives on potential next steps in this line of research.
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Chapter 1

Introduction and motivation
Many biological processes that underlie injury and disease can be characterized as
highly choreographed sequences of distinct biological events. When aiming to treat
injuries and diseases, an overarching strategy is to actively control these sequential
biological processes. Local delivery of bioactive molecules can be used to direct
individual biological events. Thus, sequences of biological events can be controlled
through localized, sequential deliveries of bioactive molecules. While there are previous
studies demonstrating sequential delivery of multiple bioactive molecules,5–7 these
studies mainly utilize biomaterials that are preprogrammed to release drug with
predetermined temporal profiles. That is, they do not provide real-time control over the
timing and sequence of deliveries. Some active materials provide the ability to trigger
biomolecular release locally at the implantation site in response to physiological cues
such as temperature and/or pH.8–12 However, these types of active materials often provide
slow response times and require stimuli that are not amenable to maintaining in vivo
homeostasis (i.e., altering temperature and pH in vivo can be disruptive to biomolecules
and tissues and can be difficult to modulate and maintain). Furthermore, clinically, there
is need for these deliveries to be adjusted in real time, based on the specifics of each
patient and their condition, as well as adjustments needed during the course of treatment
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in response to real-time patient diagnosis/prognosis.

4,13

Biomaterials that respond to

externally applied cures have been introduced to meet these requirements. For example,
biomaterials, studies have shown that materials can be designed to release bioactive
payloads in response to external signals such as electric fields14, optical signals15,
ultrasound16–18 and magnetic fields19,20. Magnetically responsive hydrogels (i.e.,
ferrogels) are particularly of interest to us because of their biocompatibility, response to
benign magnetic signals, and potential flexibility in tuning the timing and rate of the
deliveries.21–23 Ferrogels can be made by mixing iron oxide particles in the gel matrix,
allowing the gel structure to deform when exposed to magnetic fields. This deformation
results in convective purge of the molecules contained in the gel’s matrix.24–26 Biphasic
ferrogels were later developed with macroporous structures for improving the
deformation capability of these gels while using a lower concentration of the iron oxide
particles. This macroporosity improves biocompatibility of the gel with pore sizes that
are significantly enlarged, enhancing molecular and cellular transport through the gel.27
While ferrogels have been deployed to provide on-demand, magnetically
triggered deliveries, regulation of complex biological processes requires the ability to
deliver multiple bioactive compounds from the biomaterial (e.g., cytokines, proteins, etc.,
often in sequence). Therefore, we developed a dual compartment biomaterial system for
delivering critical sequences of bioactive compounds in response to externally applied
magnetic signals. This system is composed of an outer compartment in the shape of a
hollow cylinder made with porous gelatin and inner compartment which is a cylindrical
biphasic ferrogel nestled inside the hollow outer compartment. Each compartment of this
system has different design requirements and release mechanisms. The outer
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compartment is designed to diffusively release bioactive molecules that are capable of
actively recruit a cell type of interest. The inner compartment is designed to harbor a
bioactive molecule, only appreciably releasing it to the cells recruited to the outer
compartment when instructed to do so in response to an externally applied magnetic
gradient.

Thus, at its most fundamental, this two-compartment biomaterial system

provides a means to sequentially recruit and then modify the behavior of cells after
implantation, with real-time control over the timing of this sequence. This ability to
flexibly recruit and modify cells to and within a biomaterial structure is of great
importance in far-reaching biomedical and clinical scenarios. However, this dissertation
will focus on demonstrating sequential biomolecular release in a few contemporary
applications: cancer immunotherapy and wound healing (and the associated regulation of
the inflammatory response, tissue vascularization, and recruitment and differentiation of
tissue specific cell types required for properly regenerating wounds).

1.1 Cancer immunotherapy
Cancer is a group of diseases, which is characterized by abnormal and out of
control cell growth caused by mutated DNA and/or environmental effects. In 2016 about
595,690 Americans are expected to die of cancer, or about 1,630 people per day. Cancer
is the second most common cause of death in the US and accounts for nearly 1 of every 4
deaths28. This emphasizes the necessity of finding new and diverse cancer treatment
strategies. One promising cancer treatment strategy is biomaterials-based immunotherapy
in which the immune system of a patient’s own body is programed in order to initiate an
immunological attack against cancer cells 2. A more traditional (non-biomaterials-based)
immunotherapy technique involves monocytes that are extracted from the blood (Fig 1A,
3

starting at left and moving clockwise to the top) and are differentiated into dendritic cels
(DCs) (Fig. 1A, moving from top to right). These immature dendritic cells are then
presented with cancer antigens that were extracted from the patient’s cancer cells (Fig.
1A, moving from right to bottom). This causes the immature DCs to become mature and
active (Fig 1A, bottom). Finally, these activated DCs are re-infused back in to the
patient’s body (Fig. 1A, moving from bottom to left). In the body, these activated and
antigen-presenting DCs travel to the lymph nodes and present those cancer antigens to
natural killer cells (T cells). This results in the body mounting an immunological attack
against the cancer associated with that antigen.
While yielding some promising results (Fig 1, B, “cell based” survival curve in
green, 70% survival in cancer-challenged mice after 90 days), there are some
disadvantages to this ex vivo cell-based approach. One is that systemically administered
vaccines have short signal duration. Cell-based vaccines they are also very costly and
shown limited effectiveness29. Furthermore, the vast majority of DCs injected back in to
the patient rapidly die and few activated DCs (estimated at only ~0.5-2%) are able to
migrate to the lymph nodes which leads to the need for multiple administrations and
higher doses. These multiple and higher doses cause systemic toxicity problems in the
host 2. Moreover, this method requires blood withdrawal, DC cell isolation, tumor biopsy,
antigen extraction and processing, several DC modifications outside the body, and
injecting of DCs back into the body. This, in turn, requires two patient procedures, high
cost, and significant regulatory concerns 2. Because of these disadvantages, indirect
cancer immunotherapy vaccines have not been particularly successful into causing solid
tumors to regress or increasing patient survival relative to standard treatments 3.
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In order to address some of these concerns, biomaterial-based cancer
immunotherapy was introduced. In this strategy, an infection-mimicking material is
introduced in vivo, providing a site to attract and activate DCs (Fig 1C, i). 2 The
biomaterial scaffold is implanted and contains DC recruitment factor, danger signal, and
cancer antigen. The recruitment factor releases, forming a gradient, which causes DCs to
migrate towards the scaffold (Fig1C, ii). While DCs are in the scaffold, they are
subjected to the danger signal and cancer antigen left in the biomaterial (Fig1C, iii). This
results in the activation of some of the DCs (Fig1C, iv) and their homing to the lymph
node (Fig1C, v). This results in activation of an anti-tumor immunological response from
the host. This method leads to promising results. For instance, survival rates in mice that
are challenged with melanoma 14 days after drug-loaded biomaterial implantation
survive at higher rates (Fig1D, i. blue, red, and dashed black curves) compared to blank
biomaterial controls (Fig1D, ii. black curve). Notably, when optimized amounts of
GMCSF, danger signal (CpG-ODN), and antigen (tumor lysates) are loaded into these
implanted biomaterials, 90% of mice survived after 90 days (Fig1D, i blue curve).
However, when the biomaterial was implanted with mice that had existing, well
developed 13-day-old tumors, mouse survival rates were less promising (Fig1D, ii).
Even though a better survival rate was observed with loaded biomaterials in comparison
to blank biomaterials, double biomaterial implantation only yielded a 20% survival rate
after 100 days (Fig3D, ii, comparing the blue curve (Vax,2x) to the black curve (Blank)).
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i)

ii)

iii)

Biomaterial scaffold

iv)

DC recruitment factor
release/gradient

Biomaterial scaffold
(loaded with DC recruitment factors)

v)

Cancer antigen

Uneducated DC

Danger signal

Activated DC

Figure 0.1. Cancer immunotherapy strategies aim to program the body to initiate an anti-tumor
response. A. Schematic highlighting the steps involved in indirect cancer immunotherapy. Part A
adapted from Kim et al.1 B. Survival rate for cell-based vaccines (Green) vs. no vaccine (Blank).2
C. Schematic of biomaterial-based cancer immunotherapy. i. The biomaterial contains DC
recruitment factor, danger signal and cancer antigen. ii. Release of DC recruitment factor attracts
dendritic cells. iii. While DCs are in the scaffold, they are subjected to the danger signal and
cancer antigen left in the biomaterial. iv. This results in the activation of some of the DCs (orange
DCs). These activated DCs home to the lymph node. This results in activation of an anti-tumor
immunological response from the host. D. Survival rates in an in vivo mouse melanoma model
for when: (i) the mouse was implanted with biomaterial 14 days before tumor were introduced to
the mouse and (ii) the biomaterial was implanted in mice with already existing (13 days) tumors.
Parts B and D(i) adapted from Ali et al.2. Part D(ii) adapted from Ali et al.3

A potential area for improvement includes fine-tuning the timing and rate of DC
recruitment factor, danger signal and antigen presentations. For example, in the Ali et
al. system, these three biomolecules begin to diffuse out of the scaffold soon after
implantation (Fig. 1,C, ii). Therefore once a robust population of DCs has been recruited
6

to the scaffold (Fig. 1,C, iii), there are fewer danger signals and antigens left to activate
the DCs. This results in even fewer DCs being activated and reporting back to the
lymph node (Fig. 1,C, iv and v), and therefore a sub-optimal anti-cancer immunogenic
response may occur. Thus if a biomaterial system were capable of initially releasing DC
recruitment factors and delaying the presentation of danger signals and antigen
molecules, enhanced populations of activated DCs could be generated, resulting in
stronger anti-cancer immunological responses. We will therefore aim to develop and test
the reprogramming effectiveness of a biomaterial system capable of flexibly controlling
the timing and rate of these molecular deliveries in response to externally applied
magnetic fields. This biomaterial will result in a high degree of clinical significance by
improving cancer survivability and immunity and may be applicable to a wide variety of
cancer types. It will also provide a high degree of broad investigative significance by
providing a system for examining how the timing and dose of recruitment and
reprogramming agents impact immunological responses in general.
The hypothesis guiding this research is that DC activation can be improved by
delaying the release of antigens until a vigorous population of DCs has been recruited to
the biomaterial. Thus, the overarching aim for this research will be to develop an
implantable biomaterial system capable of first releasing DC recruitment factors from its
outer compartment, followed by magnetically triggered release of a model antigen. Such

7

a system may be capable of recruiting DCs and only delivering cancer antigen to
recruited DCs at optimized times when stimulated by externally applied magnetic fields.

This proposed biomaterial system consists of two compartments, similarly as
described before (Fig. 2A, i and ii). Compartment 1 will initially release DC recruitment
factor (GM-CSF) and will have a functionality to maintain recruited DCs (by having a
macro-porous structure (Fig. 2A, iii)). This compartment is made from porous gelatin and
is loaded with GM-CSF recruitment factor. Compartment 2 consists of a magnetically
deformable porous alginate structure that only appreciably releases a model antigen (Heat
shock protein 27 (HSP27)) when magnetically stimulated (Fig. 2A, iv and v). This will
result in the delivery of antigen in an on-demand, delayed manner. This combined system
will be capable of sequentially releasing DC recruitment factors, followed by releasing
antigen with magnetic stimuli (Fig.2B). The reason behind choosing these proteins for
our work is as follows. The cytokine granulocyte-macrophage colony-stimulating factor
(GM-CSF) has been identified as a stimulator of dendritic cell recruitment. 30 Heat shock
protein 27 (HSP27) is used as cancer antigen and is often a target for cancer therapy
drugs and the immune system. The massive release of HSP due to widespread tumor cell
necrosis after cytotoxic drugs can lead to CD8+ T-cell-mediated anti-tumor immune
responses.31 However, for the purposes of this dissertation, HSP27 will be used as a
model antigen. Optimizing the effectiveness of cancer antigen is beyond the scope of this
work.
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iii
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Figure 0.2. Our biomaterial will be designed to initially release DC recruitment factor followed
by magnetically triggered release of cancer antigen and danger signal. A. (i-ii) This biomaterial
system will be a dual compartment hydrogel composed of a (1) DC recruitment compartment and
(2) a magnetically responsive reprogramming delivery compartment. (iii) Compartment 1 initially
releases DC recruitment factor (GM-CSF). (iv) While DCs are being recruited, compartment 2
retains antigen (HSP27) and danger signal (single stranded nucleic acids, ssNAs). (v) When
magnetically stimulated, compartment 2 releases antigen and danger signal. Part A figure key can
be found in Figure 1’s caption. B. Desired cumulative release of various molecules from our
biomaterial vs. time.

1.2 Chronic wound healing
The proposed two-compartment, magnetically responsive biomaterial system may
also be of use in the field of chronic wound healing. In the United States, approximately
6.5 million patients are diagnosed with chronic wounds. The treatment of chronic wounds
costs more than $25 billion annually and this is expected to grow due to the increasing
cost of healthcare, an aging population, and a rise in the occurrence of diabetes and
obesity worldwide.32 The process of wound healing includes four major steps: hemostasis
(blood clothing), inflammation, proliferation, and tissue maturation.33 Even a slight
perturbation in this process can disrupt proper healing, leading to chronic wounds.
Chronic wounds are often a result of arrest in the inflammation phase of healing.33
Although inflammation critically initiates repair and helps clear infections, a prolonged
inflammatory reaction can cause considerable harm to the injury site. After an
9

appropriate duration of inflammation, this inflammatory response can be shifted to a
more pro-healing response through the delivery of cytokines like interleukin 4 (IL-4) and
interleukin 10 (IL-10). These anti-inflammatory cytokines alter the phenotype of
macrophages from pro-inflammatory (M1) to anti-inflammatory (M2), suggesting a
potentially powerful drug delivery strategy if these cytokines can be delivered in a
delayed manner.
We hypothesized that the two-compartment biomaterial system described above
would be capable of (i) initially delivering macrophage recruitment factor and factors that
would direct recruited macrophages to adopt a pro-inflammatory M1 phenotype and (ii)
magnetically delaying the release of factors that would transition recruited M1
macrophages to anti-inflammatory, pro-healing M2 phenotypes. Specifically, we propose
to design the biomaterial system to initially delivery IFN-γ and MCP-1 from the porous
outer compartment and retain and magnetically release IL-4 and/or IL-10 from the inner
ferrogel compartment. The goal of this research is to develop a wound-healing hydrogel
system that allows for the investigation into how the duration of the inflammatory period
impacts would healing. Namely, by altering the time at which magnetic stimulation is
applied, the proposed biomaterial system will be able to regulate the time point at which
the inflammatory response transitions into a pro-healing response. Critically, this is a
simple parameter to alter between experiments, enabling rapid investigations into how the
timing of these biological processes impact regeneration.
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Chapter 2

Review of Literature
2.1 Introduction
The ability to produce temporally complex delivery profiles in an on-demand
manner is pervasively needed in a wide range of biomedical and clinical scenarios,
ranging from cancer treatment to tissue engineering. Stimuli-responsive biomaterials
provide a potential means of providing on-demand regulation over temporally complex
delivery profiles.1–4 Some stimuli-responsive materials can be preprogrammed to respond
to environmental cues such as pH5,6 or temperature7–9 whereas others can be triggered ondemand via externally applied signals. For example, materials can be engineered to
release payloads in response to magnetic, electric, ultrasound, and optical signals.10–13
The focus of this review is to outline and discuss the potential of magnetically
responsive materials for providing on-demand regulation of complex therapeutic delivery
profiles. This focus is founded in a number of key factors. First, magnetically responsive
biomaterials typically contain magnetic particles14–16, which are widely used in
biomedical applications. For example, magnetic nanoparticles17,18 and magnetic
liposomes19 can be synthesized and used as drug carriers. The use of iron oxide
nanoparticles as magnetic imaging contrast enhancers has made its way to clinical
trials20,21 and are extensively used in magnetic resonance imaging (MRI).22 Magnetic
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particles are also used for targeting purposes23 and hyperthermia-based treatments (i.e.,
cancer treatment involving heating up the cancer cells to temperature between 43°C to
46°C when cell viability drops and becomes more vulnerable to chemotherapy and
radiation). 24–26 Furthermore, magnetic fields similar to those used in these treatments are
widely used in everyday scenarios (e.g., at airport security, at store exits, in MRIs, and
even in some children toys) and have been demonstrated to be harmless to the human
body.22,27 Taken altogether, this well-established track record of using magnetic particles
and magnetic field stimulation creates a strong precedence for their diagnostic and
therapeutic use. This suggests that magnetic nanoparticle integration into drug delivery
systems and remote stimulation using magnetic fields may be a viable option for
achieving on-demand control over biomolecular deliveries.
This review will concentrate on hydrogel-based drug delivery systems that are
integrated with magnetic particles, endowing them with on-demand delivery capabilities
when subjected to remotely applied magnetic fields. Hydrogels are used significantly in
drug delivery applications due to a number of desirable features.28,29 For example, they
can absorb water up to 30% of their dry weight and can be made from biocompatible
polymers. They can also be chemically and mechanically modified to better interface
with tissues.30–33 Ferrogels are hydrogels that have been integrated with iron oxide
particles in their polymeric network and their preparation method is very well
established.34–36 Here, we will categorize the drug release mechanisms from ferrogels and
will discuss the tunable parameters effecting each release mechanism. This, in turn, may
shed light on how magnetically responsive ferrogels can be designed to achieve magnetic
control over more temporally complex drug delivery profiles. We will then proceed to
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highlight the importance of producing multi-drug release profiles in an on-demand
manner and underscore the limited amount of work being done in this area.

2.2

Magnetically triggered release mechanisms

2.2.1

Inductive heating, agitation, or melting of polymer structures
Hydrogels can be designed to change phase (e.g., collapse, degrade, or swell)

when inductively heated or agitated under magnetic stimulation, leading to release of
payloads.37–39 The super paramagnetic iron oxide nanoparticles (SPIONs) inside these
hydrogels can absorb energy from high-frequency magnetic fields, which in turn leads to
swelling or collapse of the hydrogel matrix due to changes in temperature. This inductive
heating occurs when an alternating magnetic field (AMF) is applied to SPIONs. Heat is
generated due

to Neel and Brownian relaxation phenomena.40,41 This energy then

transfers to the hydrogel’s polymer matrix which can lead to conformational changes
such as polymer collapse or degradation (Figure 1).42 In a study by Hu et al.,43 the authors
were able to show the pulsatile delivery of vitamin B12 loaded in the polymeric system.
This system was made by embedding iron oxide nanomagnets with average diameter of
40 nm within gelatin polymer network crosslinked with genipin. When a high frequency
magnetic field was applied, the nanoparticles twisted and shaken, causing the polymeric
network to decompose and release its content. Vibrations of the particles were also shown
to increase the local temperature of hydrogel as well, which could potentially be
problematic if this system were used for delivering more sensitive molecules such as
proteins (which can denature at higher temperatures, rendering them bio-inactive).
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Figure 0.1. Schematic of heat-inductive release mechanism from hydrogels triggered with
magnetic field. Figure copied from Brundo et al.44

There are several other notable examples of hydrogel systems that exploit
inductive heating/agitation from magnetic fields to externally regulate drug delivery
profiles from hydrogel systems. For example, N-isopropylacrylamide (NIPAAm) is a
temperature responsive polymer with a lower critical transition temperature (LCST)
between 30 and 35°C.45 In one study, NIPAAm gels were made in disk shapes (15 mm
diameter and 0.5 mm thickness) and iron oxide nanoparticles (25 nm in diameter) were
integrated into the gels. The release of vitamin B12 loaded in these gels was studied in the
presence of an AMF (2.98 kA/m @ 297 Hz). It was shown that when the AMF was
applied, heat generation of the magnetic nanoparticles increased the temperature of the
NIPAAm network above the LCST, leading to gel collapse and excretion of the water out
of the polymer matrix. This process increased the release rate of the B12 from the
polymeric matrix.46

In another study done by Hoare et al.47, thermo-responsive

NIPAAm-based nanogels were incorporated in ethyl cellulose-based membrane made
containing iron oxide nanoparticles. As in the previous study, this gel formulation was
used due to its ability to change its volume at different temperatures When an alternating
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magnetic field was applied to these nanogels, the iron oxide nanoparticles contained in
the membrane heated up and rose beyond physiological temperatures to 50°C. This
heating caused a ~400 nm decrease in the diameter of the nanogels which then led to an
outward flux of sodium fluorescein from the drug reservoir (Figure 2).

Figure 0.2. Schematic of Magnetically responsive membrane triggered for drug release.
Figure copied from Hoare et. al.47

Elsewhere, Lu et al.48 incorporated the ferromagnetic gold coated cobalt
nanoparticles inside 5-μm diameter microcapsules made from poly(sodium styrene
sulfate)/poly(allylamine hydrochloride). When an AMF was applied, the embedded
Co@Au nanoparticles vibrated and disturbed the structure of the microcapsule wall,
leading to increases in the permeability of the microcapsule wall. This, in turn, lead to
enhanced diffusion of FITC-labeled dextran across the capsule wall (Figure 3).

19

Co@Au nnoparticles
Polyelectrolyte layer
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Figure 0.3. Illustration of effect of magnetic field on drug diffusion across
microstructures. Figure adapted from Lu et al.,48

2.2.2

Physical changes in response to magnetic fields
Magnetic fields can be used to generate forces on magnetic particles and these

forces can be used to directly impact physical structures in hydrogel that impact payload
retention and release characteristics. For example, magnetic particles can be entrapped
within a hydrogel’s polymer matrix (Figure 4, left). In the presence of a DC magnetic
gradient (e.g., from a hand-held magnet), forces are exerted on the entrapped magnetic
particles. This force moves the particles towards the magnet and hydrogel matrix deforms
due to this particle movement (Figure 4, right). This deformation results in decrease in
gel volume and convective purging of water and loaded drugs from the gel system
(Figure 4, right, red dots leaving matrix). For instance, Zhao et al.49 demonstrated that
while some ferrogel deformation could be achieved by simply incorporating iron oxide
particles into an alginate hydrogel matrix, generation of a highly macroporous hydrogel
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structure (i.e., through a cryogelation approach) yielded much softer and more
magnetically compressible ferrogels that were capable of efficiently delivering biological
payloads (i.e., chemotherapeutics, proteins, DNAs, and even cells) when subjected to
simple hand-held magnets. Zhao et al.49 went on to demonstrate efficient delivery of
cellular payloads in vivo using these same macroporous ferrogels. Subsequent
improvements upon these macroporous ferrogels include a biphasic design which enables
efficient deformations and payload deliveries using decreased concentrations of iron
oxide35 Additionally, these biphasic ferrogels exhibited increased porosity (for better
cellular infiltration) and decreased toxicity (due to lower iron oxide concentrations) for
tissue engineering and other in vivo applications. In fact, when implanted in vivo,
periodic magnetic deformation of these biphasic gels where shown to reduce
inflammation and enhance muscle regeneration.50

Figure 0.4. Schematic of hydrogel deformation triggered with DC graded magnetic field.
Figure adapted from Brundo et al.44

Magnetically actuated movement, aggregation, and/or orientation of iron oxide
particles can also be used as a means to regulate drug release. For example, magnetically
actuated aggregation of magnetic particles can be used to decrease drug delivery rates. A
fundamental example of this was demonstrated by Guowei et al.,51 in which a porous
membrane was introduced that seals a depot of magnetic nanospheres containing drug. A
21

magnetic field was used to aggregate the magnetic particles in a manner that prevented
diffusion of the drug through the membrane. In a separate study by Liu et al.,52 a
poly(vinyl alcohol) hydrogel was fabricated with 150-500 nm Fe3O4 nanoparticles
incorporated into the gel. This ferrogel was used as a membrane that sealed a drug depot.
The application of the direct current (DC) magnetic field lead to the aggregation of the
Fe3O4 nanoparticles in the ferrogel membrane, thus decreasing the porosity of the ferrogel
membrane and leading to decreased diffusion of the drug through membrane. Similar
ability to modulate drug release using a magnetic field was observed in another study
where gelatin ferrogels were used as a membrane.53 In another study, superparamagnetic
iron oxide nanoparticles were embedded inside the Pluronic F127 micelles with diameter
around 13 nm. Indomethacin was loaded in another group of micelles and both groups
were mixed together inside an aqueous environment (Figure 5, i). Upon application of a
magnetic field, SPIONs orient and approach each other, thus perturbing the micelle
structures by squeezing them and forcing out the indomethacin drug (Figure 5, ii).54
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Figure 0.5. Illustrations drug-containing micelles being disrupted in a magnetic field.
Figure adapted from Qin et al.54

Movement of magnetic particle-laden materials can also be used to modulate drug
delivery through the use of micropumps. In a study by Wang et. al.,55 a microdevice was
developed with a drug reservoir placed between two PDMS membranes (Figure 6A, red
drug reservoir sandwiched between two blue, flexible PDMS membranes). An iron oxide
PDMS composite disk was placed underneath one of the membranes (Figure 6A, yellow
composite subjacent to the bottom blue PDMS membrane). This arrangement restricted
the diffusion of drug when no magnetic field was applied, as the drug reservoir remained
sealed (Figure 6B). However, when a magnetic field was applied, the magneticnanoparticle-laden composite would be attracted to the magnet, thus deforming the
PDMS membranes, resulting in an arrangement that would facilitate the release of the
drug reservoir (Figure 6C). This system was demonstrated successfully both in vitro and
in vivo. Researchers have developed similar battery-less magnetically responsive drug
delivery devices for delivering docetaxel for treatment of diabetic retinopathy56 and ondemand insulin administrations57.
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A

B

C

Figure 0.6. The schematic of the intravitreal implantable magnetic micropump. A) Cross
section view of the micropump. B) The diffusion of the drug is prevented when there is no
magnetic field. C) In the presence of magnetic field, drug releases upward. Figure adapted from
Wang et. al55

2.3

Tunable parameters affecting drug release
There are several material parameters that impact the retention and magnetically

stimulated release of payloads from these biomaterial systems such as ferrogel pore size,
magnetic particle concentration and size. As with other hydrogel-based materials, matrix
porosity is a critical parameter influencing release characteristics. Generally, a more open
more structure results in higher levels of release both unstimulated diffusive release and
magnetically stimulated release. However, in many applications, it is desirable to achieve
low-levels of unstimulated release and much greater levels of release upon magnetic
stimulation. Thus, hydrogel porosity must be tuned to achieved desirably low levels of
unstimulated release and desirably high levels of stimulated release.

Hydrogel

nanoporosity (i.e., the mesh structure of the polymeric matrix) can be tuned by altering
polymer and crosslinker concentration.31–33 Hydrogel macroporosity (i.e., large, often
interconnected disruptions in the pores macrostructure) can drastically increase surface
area of the gel as well as magnetic compressibility.35,49It was shown by Zhao et al.49that a
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freeze-drying method could be used to generate macroporous ferrogels and that the
macropores of the ferrogel could be controlled by the temperature at which the gel was
frozen.
Regarding porosity, the incorporation of iron oxide particles into the hydrogel
matrix required to endow the hydrogel with magnetic responsiveness has been shown to
decrease the porosity of the ferrogels. For both ferrogels that rely on magnetic
heating/agitation vs. deformation/aggregation/alignment, this change in porosity certainly
impacts release characteristics. Specifically, for magnetically deformable hydrogels,
higher concentrations of iron oxide reduces hydrogel porosity, thus reducing magnetic
deformability, thus reducing the amount of drug released when the gel is magnetically
deformed.35 However, despite this, increased concentrations of iron oxide may provide
more magnetic force generation on the ferrogel, thus enhancing magnetic deformability.
Thus, iron oxide concentration is associated with two competing parameters: (i) the
ability to exert magnetic force for deforming structures and (ii) the inability to deform
structures due to changes in porosity and/or material stiffness. For drug deliveries that
rely on magnetic deformation, Cezar et al.35 demonstrated that optimal concentrations of
magnetic particles exist for maximum deformation and drug delivery, with too low of
concentrations not generating sufficient force and too high of concentrations resulting in
gels that are too stiff. However, Cezar et al. went on to show that these competing
parameters could be decoupled by partitioning a hydrogel into two regions: (i) a
magnetic-particle-free region that can be designed to be as porous and deformable as
possible and (ii) a magnetic-particle-laden region that can be densely packed with
particles to generate maximum magnetic force. For delivery strategies involving
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magnetic heating/agitation, while magnetic particle concentration likely impacts
stimulated and unstimulated diffusion out of the hydrogel58, studies have mostly shown
that increasing magnetic particle concentration increases the degree of heating/agitation,
and thus enhances stimulated drug release.37,38,59Magnetic particle concentration also
impacts the nature by which magnetic fields penetrate and/or are absorbed within the
hydrogel structure. In a study conducted by Liu et al.60 on controlled permeation of drug
from ferrogels, sensitivity of PVA-based ferrogels to magnetic fields were studied in
terms of permeability coefficient (P) and partition coefficient (H). Results showed that
for optimum magnetization there is a critical parameter of free volume per nanoparticle
that needs to be met. For their particular gel system, they found 17-34% iron oxide in
PVA ferrogels was necessary for optimal magnetic sensitivity.
For both magnetic heating/agitation- and magnetic deformation-based delivery
strategies, magnetic particle size also impacts release characteristics. For magnetic
heating, the use of particles smaller than 20 nm reduces eddy currents which in turn
restricts the heating of the particles.23 Therefore, traditionally, SPIONs with diameters
between 5-28 nm are used as they heat most efficiently when exposed to AMFs in the
radio-frequency range (i.e., 100s of kHz), which are simple and relatively inexpensive to
produce.61 For magnetic deformation-based drug delivery strategies, magnetic particle
size also plays a key role in determining delivery characteristics. For example, it was
shown that when subjected to the same graded DC magnetic field, ferrogels made with
smaller iron oxide particles (less than 50 nm particle size) had significantly lower
deformation and drug delivery capabilities compared to ferrogels made with larger iron
oxide particles (less than 5 µm in size).35 Thus, if heating/agitation is desired,
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nanoparticle-sized SPIONs are desirable whereas if force/deformation is desired, larger
(or aggregated) magnetic particles are desired.
Beyond material parameters, the parameters associated with the applied magnetic
field itself play a key role in influencing magnetically stimulated release. Specifically, the
amplitude, gradient, frequency, proximity, and directionality of the magnetic field can
impact release profiles from ferrogels. Higher amplitudes can generate more magnetic
heating/agitation and/or more force generation38,62, though when using larger,
ferromagnetic particles the gradient of the magnetic field is more critical than the
amplitude per se. Certainly, proximity of the magnetic source impacts both the amplitude
and relative gradient of the magnetic signal, so placement of the ferrogel relative to the
magnetic source is a critical consideration.
Regarding frequency, its impact on release can be quite complex. At relatively
low frequencies, graded magnetic fields can efficiently exert forces on ferromagnetic
particles, thus regulating retention and release characteristics in a number of manners (see
Section 2.2).2,49–57,63 Kennedy et al.63 demonstrated that even at these relatively low
frequencies (1 – 550 Hz), the frequency of magnetic stimulation could be used to regulate
the rate of drug release from magnetically deformable ferrogels. Specifically, it was
demonstrated that molecules did not efficiently release from ferrogels at too low or high
of frequencies, but rather, optimally released at some middle frequency (depending on the
how the molecule interacted with the hydrogel matrix). This was explained in terms of (i)
low frequencies infrequency purging molecules from the gel structure but (ii) high
frequencies not efficiently deforming the gel structure due to exceeding the mechanical
resonance of the gel. Thus, a given molecule will exhibit a release rate vs. frequency
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signature and that different molecules exhibit different release rate vs. frequency
signatures. At higher frequencies (< 100 kHz), SPIONs can efficiently adsorb energy
from AMFs, resulting in a number of different means to thermally or agitatedly engender
release.2,37–43,47,48,64 However, there is a strong relationship between the frequency of
magnetic stimulation, the size and type of the SPION, and the efficiency of AMF
absorption.40,65,66 For example, for a Fe3O4 SPION of a given diameter, its heating is a
function of AMF frequency, being optimally resonant at a specified frequency. This
heating vs. frequency signature is different for different sizes and types of SPIONs, but
generally, larger SPIONs are more efficiently heated at AMFs with longer wavelengths
(i.e., lower frequencies) and smaller SPIONs are more efficiently heated at AMFs with
shorter wavelengths (i.e., higher frequencies).
Finally, the orientation or directionality of the applied magnetic field can impact
release characteristics. For example, hand held magnets can align or move magnetic
particles in specified directions based on the field lines emanating from the magnet
(which is, in turn, based on the way the direction that the magnetic is oriented/held). This
orientation/alignment can lead to aggregation of the particles or compression of the gel
matrix in specified directions. This can greatly impact release. For instance, when using
the system described in Figure 6,55 orientation of the magnet such that the magnetic
PDMS disk (yellow on schematic) is pulled downward would result in tightening of the
seal, restricting drug release. Only when pulled upwards would this system provide
release. Likewise, for a biphasic ferrogel,35 orientation of the magnet gradient must result
in pulling the iron-oxide-laden region of the gel against the soft, deformable region to
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appreciably trigger drug release. If the magnetic gradient is aligned otherwise, the ironoxide-laden region will not deform the deformable region, thus limiting drug delivery.

2.4

Perspectives on generating temporally complex drug delivery profiles using

magnetically responsive hydrogels
2.4.1

Introduction
While the section above outlines the many number of parameters that can

influence magnetically triggered release, this parametric abundance provides a wealth of
strategies for customizing release properties and uncovers the potentiality of generating
more complex delivery profiles using magnetic fields. The ability to generate more
complex delivery profiles (e.g., temporally dynamic deliveries that change vs. time and
delivery profiles that involve more than one drug such as sequential deliveries) is
pervasively required in modern medicine. Illnesses and injuries are often associated with
the interruption or distortion of natural sequences of biological events. Thus,
therapeutically regulating these sequential biological processes requires sequentially
delivering multiple bioactive therapeutics with the proper dosing, timing, and
sequence.29,67–70 Beyond sequential deliveries for therapeutic control over sequential
biological processes, the temporal profile of single drug deliveries can be critical for
optimizing therapeutic outcome. For example, chronotherapies involve pulsing the
delivery of anticancer drugs to increase drug concentration when the tumor is
metabolically active and to decrease it when not metabolically active.29,67,71,72 These
pulsatile delivery profiles can also help prevent the tumor from developing an adaptive
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resistance to the anticancer drugs.73,74 Thus, strategies must be developed to generate
temporally complex delivery profiles (i.e., pulsed deliveries) and multi-drug, sequential
delivery profiles. This section will explore existing strategies for obtaining these types of
deliveries and propose potential strategies for obtaining these deliveries moving forward.

2.4.2

Existing strategies
A key advantage to using magnetically responsive hydrogels is that a magnetic

field can be applied at times when changes in the delivery profile are desired. Simply put,
changes in delivery profile can be regulated in an on-demand manner. Therefore,
magnetically responsive hydrogels are theoretically capable of generating temporally
complex delivery profiles such as pulsatile deliveries. In a study done by Hu et al, 43 the
pulsatile release of vitamin B12 from a gelatin ferrogel was investigated. Ferrogels were
exposed to5-minute high-frequency magnetic field (HFMF) pulses with 180 minutes of
no magnetic field in between each stimulation. A burst increase in the release rate was
observed during each stimulation period (Figure 7). However, a gradual reduction in the
release rate was observed over time.
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Figure 0.7. Pulsatile drug release rate from gelatin loaded with iron oxide nanoparticles
(40 nm in diameter) under 5 minute period of HFMF every 180 minute. Figure taken from Hu et
al.43

Elsewhere, Satarkar et. al64 also demonstrated pulsatile delivery of vitamin B12
from (NIPAAm)-based ferrogels. The results showed approximately 6 times increase in
the release upon AMF magnetic stimulation for 10 minutes every 20 minutes. Again,
however, while a pulsatile delivery profiles was achieved, a gradual decrease in release
rate was observed over time upon subsequent pulsing (Figure 8). This may have been due
to a short recovery period of 20 minutes where the gel structure doesn’t have enough time
to recover and stay collapsed, thus, limiting diffusive release over time.
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Figure 0.8. Release of Vitamin B12 from the nanocomposite upon application of AMF (F).
% represents particle loaded by weight in nanocomposite. (N=3±SD). Figure copied from
Satarkar et al.64

In another study by Emi et al.,75 magnetically deformable alginate hydrogels were
used to generate pulsatile mitoxantrone delivery profiles. However, in this study, pulsatile
profiles were produced that were specifically similar to those demonstrated to be highly
effective in killing melanoma cells in vitro (one 1-hr pulse of increased mitoxantrone per
day for 3 days). This required generating pulsatile delivery profiles over days rather than
hours. However, just as in the studies described above,43,64 over the course of these 3-day
experiments, the amount of drug released during magnetic stimulation significantly
decreased each day, resulting in pulsatile delivery profiles with diminishing pulse
heights. However, to compensate for this, Emi et al. used higher frequencies of magnetic
stimulation on subsequent days to maintain delivery rates. This progressive increase in
frequency resulted in pulsatile delivery profiles with uniform pulse heights (Figure 9A).

32

Figure 0.9. A) Demonstration of pulsatile mitoxantrone delivery profiles using magnetic
stimulation. Adapted from Emi et al. 75 B) Demonstration of sequential delivery of two model
drugs (dextrans: lower affinity in blue, higher affinity in red) vs. time. Adapted from Kennedy et
al. 63

As mentioned above, generation of multi-therapeutic, sequential delivery profiles
is also critical in directing biological processes pertinent to injury and disease. While
little work has been done in using magnetically responsive hydrogels to achieve these
types of complex delivery profiles, Kennedy et al.

63

demonstrated that different

molecules with different affinities to a ferrogel’s matrix exhibited different release rate
vs. frequency (1 – 550 Hz). For instance, this study demonstrated that a dextran with a
lower affinity to the alginate ferrogel preferentially released from the ferrogel when
stimulated at 1 Hz, whereas a dextran with a higher affinity preferentially released when
stimulated at 20 Hz. Thus, a sequential delivery profiles was achieved by first triggering
the low affinity dextran to release by stimulating at 1 Hz at earlier time points, followed
by triggered release of the high affinity dextran when stimulating at 20 Hz at later time
points (Figure 9B). In another study by Tolouei et al.,76 a dual compartment biomaterial
system was introduced that was composed of a gelatin outer compartment surrounding a
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ferrogel inner compartment. This study went on to demonstrate that the outer
compartment could initially release pro-inflammatory cytokines and the inner ferrogel
could delay the delivery of anti-inflammatory cytokines (until magnetically triggered to
do so). This 2-copartment biomaterial system was thus capable of generating sequences
of pro- and anti-inflammatory cytokine deliveries using the timing of the magnetic
stimulation to control the duration between these two deliveries.

2.4.3

Prospective strategies
Despite the importance of developing biomaterials capable of with temporarily

complex, multi drug delivery capabilities, there are only a limited number of examples of
magnetically responsive systems demonstrating this ability (section 4.2). However, as
mentioned above, there are a wealth of tunable parameters that may be employed in
future studies that may enable the production of these more complex deliveries. For
instance, the location, direction, and/or shape of the applied magnetic field could be used
to independently trigger specified release events if a ferrogel is constructed in a
compartmentalized manner. If different magnetically compressible compartments are
loaded with different drugs (Figure 10A, i: Drugs A (red), B (blue), and C (green)) then
an appropriately shaped magnet can be used to only trigger release from a targeted
compartment (Figure 10A, ii: only the compartment containing drug B (blue) is
compressed). Likewise, the compartments containing drugs A and C can be triggered at
on-demand timepoints. This system could coordinate complex delivery profiles involving
all three drugs.

Similar arrangements could also be used to control not only the

selectivity of which drug is being delivery and when, but also some degree of control
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over the directionality of drug delivery. For example, if the gel is compartmentalized in a
way where different compartments will be deformed when a magnetic is applied from
different directions (Figure 10B), then the directionality of drug release can be
magnetically regulated. This compartmentalized approach can be applied to membrane
reservoir system as described in Section 2 of this chapter as well to achieve control over
multiple drug deliveries.

Figure 0.10. A) Illustration of a 3-compartment system for independently triggered deliveries of 3
different drugs. B) Illustration of a compartmentalized hydrogel that can deform, releasing drugs
in different directions, depending on from what direction the magnet is applied.

Another way by which magnetic control over multiple deliveries can be achieved
is to combine independent mechanisms to independently trigger release. That is, high-
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frequency AMFs typically trigger release by heating or physical agitation or disruption
and most efficiently influence nano-scale SPIONs. Low-frequency, graded magnetic
fields typically trigger release by exerting forces on or aggregating relatively large
magnetic particles embedded in the gel. A hydrogel can potentially be constructed by
combining these separate elements. One drug (Figure 11, i: red dots) can be loaded into a
region of the gel that can deform in response to a graded, low-frequency magnetic field,
and a second drug (Figure 11, i: orange lines in blue bubbles) can be loaded into
structures that heat, melt, or are disrupted by high-frequency AMFs. Thus, an AMF can
be used A
to independently trigger release of one drug (Figure 11, ii: orange payloads
i
ii
Drug A can be usedMicrogel
released from blue bubbles) and DC graded magnetic fields
to independently
trigger release of the other drug (Figure 11, iii:

B
i

Drug B
Hand-held magnet
Drug C
Iron Oxide
particle
deformation
and
release of
red
dots).alternating
High
Frequency
Drug D
magnetic field

ii

iii

Figure 0.11. Illustration of hydrogel system with the ability to release different drugs when
stimulated using different magnetic signals.

Finally,

when

using

SPIONs

and

AMFs,

the

efficiency

of

heating/agitation/disruption is dependent on both the frequency of the AMF and the
diameter of the SPION. As mentioned before, generally, smaller SPIONs are more
efficiently influenced by higher frequency AMFs whereas larger SPIONs are more
efficiently influenced by lower frequency AMFs. This can be exploited in a system where
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different structures containing different drugs are preferentially disrupted at different
frequencies. Specifically, structures/depots containing drug 1 can be integrated with
smaller SPIONs that preferentially respond to higher-frequency AMFs (Figure 12,
bubbles decorated with small black dots, containing red drug). Other structures/depots
containing a different drug can be integrated with larger SPIONs that preferentially
respond to lower-frequency AMFs (Figure 12, bubbles decorated with larger black dots,
containing blue drug). Therefore, when stimulated using a relatively low-frequency
AMF, the structures decorated with larger SPIONs will preferentially be disrupted,
releasing their payloads (Figure 12, middle). When stimulated using a relatively highfrequency AMF, structures decorated with larger SPIONs will preferentially release their
payloads (Figure 12, left).

Figure 0.12. Illustration of system containing drug depots that differentially respond to AMFs of
different frequencies. This enables frequency-dependent control over what drug is being delivered
when.

37

2.5 References
1.

Magnani M. Drug delivery and targeting system. Emerg Ther Targets.
1998;2(1):145-146. doi:10.1517/14728222.2.1.145

2.

Brudno Y, Mooney DJ. On-demand drug delivery from local depots. J Control
Release. 2015;219:8-17. doi:10.1016/j.jconrel.2015.09.011

3.

Jeong B, Gutowska A. Lessons from nature: Stimuli-responsive polymers and their
biomedical

applications.

Trends

Biotechnol.

2002;20(7):305-311.

doi:10.1016/S0167-7799(02)01962-5
4.

Ferreira NN, Ferreira LMB, Cardoso VMO, Boni FI, Souza ALR, Gremião MPD.
Recent advances in smart hydrogels for biomedical applications: From selfassembly to functional approaches. Eur Polym J. 2018;99(November 2017):117133. doi:10.1016/j.eurpolymj.2017.12.004

5.

Gupta P, Vermani K, Garg S. Hydrogels: From controlled release to pH-responsive
drug delivery. Drug Discov Today. 2002;7(10):569-579. doi:10.1016/S13596446(02)02255-9

6.

Balamuralidhara V, Pramodkumar TM, srujana N, et al. pH sensitive drug delivery
systems:

A

review.

Am

J

Drug

Discov

Dev.

2011;1(1):28-48.

doi:10.39.23/ajdd.2011.24.48
7.

Bromberg LE, Ron ES. Temperature-responsive gels and thermogelling polymer
matrices for protein and peptide delivery. Adv Drug Deliv Rev. 1998;31(3):197221. doi:10.1016/S0169-409X(97)00121-X
38

8.

Xu FJ, Kang ET, Neoh KG. pH- and temperature-responsive hydrogels from
crosslinked triblock copolymers prepared via consecutive atom transfer radical
polymerizations.

Biomaterials.

2006;27(14):2787-2797.

doi:10.1016/j.biomaterials.2006.01.003
9.

Singh NK, Lee DS. In situ gelling pH- and temperature-sensitive biodegradable
block copolymer hydrogels for drug delivery. J Control Release. 2014;193:214227. doi:10.1016/j.jconrel.2014.04.056

10.

Alvarez-Lorenzo C, Bromberg L, Concheiro A. Light-sensitive intelligent drug
delivery systems. Photochem Photobiol. 2009;85(4):848-860. doi:10.1111/j.17511097.2008.00530.x

11.

Kennedy S, Bencherif S, Norton D, Weinstock L, Mehta M, Mooney D. Rapid and
Extensive Collapse from Electrically Responsive Macroporous Hydrogels. Adv
Healthc Mater. 2014;3(4):500-507. doi:10.1002/adhm.201300260

12.

Huebsch N, Kearney CJ, Zhao X, et al. Ultrasound-triggered disruption and selfhealing of reversibly cross-linked hydrogels for drug delivery and enhanced
chemotherapy.

Proc

Natl

Acad

Sci

U

S

A.

2014;111(27):9762-9767.

doi:10.1073/pnas.1405469111
13.

Priya James H, John R, Alex A, Anoop KR. Smart polymers for the controlled
delivery of drugs – a concise overview. Acta Pharm Sin B. 2014;4(2):120-127.
doi:10.1016/j.apsb.2014.02.005

14.

Oh JK, Park JM. Iron oxide-based superparamagnetic polymeric nanomaterials:
Design, preparation, and biomedical application. Prog Polym Sci. 2011;36(1):16839

189. doi:10.1016/j.progpolymsci.2010.08.005
15.

Barbucci R, Giani G, Fedi S, Bottari S, Casolaro M. Biohydrogels with magnetic
nanoparticles as crosslinker: Characteristics and potential use for controlled
antitumor

drug-delivery.

Acta

Biomater.

2012;8(12):4244-4252.

doi:10.1016/j.actbio.2012.09.006
16.

Medeiros SF, Santos AM, Fessi H, Elaissari A. Stimuli-responsive magnetic
particles for biomedical applications. Int J Pharm. 2011;403(1-2):139-161.
doi:10.1016/j.ijpharm.2010.10.011

17.

Laurent S, Forge D, Port M, et al. Magnetic Iron Oxide Nanoparticles: Synthesis,
Stabilization, Vectorization, Physicochemical Characterizations, and Biological
Applications (vol 108, pg 2064, 2008). Chem Rev. 2008;108(6):2064-2110.
doi:Doi 10.1021/Cr900197g

18.

Estelrich J, Escribano E, Queralt J, Busquets MA. Iron oxide nanoparticles for
magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci.
2015;16(4):8070-8101. doi:10.3390/ijms16048070

19.

Preiss MR, Bothun GD. Stimuli-responsive liposome-nanoparticle assemblies.
Expert

Opin

Drug

Deliv.

2011;8(8):1025-1040.

doi:10.1517/17425247.2011.584868
20.

Yilmaz A, Rösch S, Yildiz H, Klumpp S, Sechtem U. First multiparametric
cardiovascular magnetic resonance study using ultrasmall superparamagnetic iron
oxide nanoparticles in a patient with acute myocardial infarction: New vistas for
the clinical application of ultrasmall superparamagnetic iron oxide. Circulation.
40

2012;126(15):1932-1934. doi:10.1161/CIRCULATIONAHA.112.108167
21.

Iv M, Telischak N, Feng D, Holdsworth SJ, Yeom KW, Daldrup-Link HE. Clinical
applications of iron oxide nanoparticles for magnetic resonance imaging of brain
tumors. Nanomedicine. 2015;10(6):993-1018.

22.

Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: Current
status of clinical application. Quant Imaging Med Surg. 2011;1(Dcc):35-44.
doi:10.3978/j.issn.2223-4292.2011.08.03

23.

Chalovich JM, Eisenberg E. Cancer Theranostics: The Rise of Targeted Magnetic
Nanoparticles.

Magn

Reson

Imaging.

2013;31(3):477-479.

doi:10.1016/j.immuni.2010.12.017.Two-stage
24.

Ang KL, Venkatraman S, Ramanujan R V. Magnetic PNIPA hydrogels for
hyperthermia applications in cancer therapy. Mater Sci Eng C. 2007;27(3):347351. doi:10.1016/j.msec.2006.05.027

25.

Shinkai M. Functional magnetic particles for medical application. J Biosci Bioeng.
2002;94(6):606-613. doi:10.1016/S1389-1723(02)80202-X

26.

Purushotham S, Ramanujan R V. Thermoresponsive magnetic composite
nanomaterials for multimodal cancer therapy. Acta Biomater. 2010;6(2):502-510.
doi:10.1016/j.actbio.2009.07.004

27.

Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug
delivery.

Adv

Drug

Deliv

doi:10.1016/j.addr.2008.03.018

41

Rev.

2008;60(11):1252-1265.

28.

Knipe JM, Peppas NA. Multi-responsive hydrogels for drug delivery and tissue
engineering

applications.

Regen

Biomater.

2014;1(1):57-65.

doi:10.1093/rb/rbu006
29.

Peppas NA, Leobandung W. Stimuli-sensitive hydrogels: Ideal carriers for
chronobiology and chronotherapy. J Biomater Sci Polym Ed. 2004;15(2):125-144.
doi:10.1163/156856204322793539

30.

Levental I, Georges PC, Janmey PA. Soft biological materials and their impact on
cell function. Soft Matter. 2007;3(3):299-306. doi:10.1039/B610522J

31.

Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev.
2012;64(SUPPL.):18-23. doi:10.1016/j.addr.2012.09.010

32.

Lee KY, Mooney DJ. Hydrogels for tissue engineering.

Chem Rev.

2001;101(7):1869-1879. doi:10.1021/cr000108x
33.

Drury JL, Mooney DJ. Hydrogels for tissue engineering: Scaffold design variables
and applications. Biomaterials. 2003;24(24):4337-4351. doi:10.1016/S01429612(03)00340-5

34.

Auernhammer GK, Collin D, Martinoty P. Viscoelasticity of suspensions of
magnetic particles in a polymer: Effect of confinement and external field. J Chem
Phys. 2006;124(20). doi:10.1063/1.2199847

35.

Cezar C a, Kennedy SM, Mehta M, et al. Biphasic Ferrogels for Triggered Drug
and Cell Delivery. Adv Healthc Mater. 2014:1-8. doi:10.1002/adhm.201400095

36.

Gonzalez JS, Nicolás P, Ferreira ML, Avena M, Lassalle VL, Alvarez VA.
42

Fabrication of ferrogels using different magnetic nanoparticles and their
performance

on

protein

adsorption.

Polym

Int.

2014;63(2):258-265.

doi:10.1002/pi.4498
37.

Crippa F, Moore TL, Mortato M, et al. Dynamic and biocompatible thermoresponsive magnetic hydrogels that respond to an alternating magnetic field. J
Magn

Magn

Mater.

2017;427(October

2016):212-219.

doi:10.1016/j.jmmm.2016.11.023
38.

Brazel CS. Magnetothermally-responsive nanomaterials: Combining magnetic
nanostructures and thermally-sensitive polymers for triggered drug release. Pharm
Res. 2009;26(3):644-656. doi:10.1007/s11095-008-9773-2

39.

Liu TY, Hu SH, Liu DM, Chen SY, Chen IW. Biomedical nanoparticle carriers
with combined thermal and magnetic responses. Nano Today. 2009;4(1):52-65.
doi:10.1016/j.nantod.2008.10.011

40.

Rosensweig REE. Heating magnetic fluid with alternating magnetic field. J Magn
Magn Mater. 2002;252(0):370-374. doi:10.1016/S0304-8853(02)00706-0

41.

Hergt R, Dutz S, Müller R, Zeisberger M. Magnetic particle hyperthermia:
Nanoparticle magnetism and materials development for cancer therapy. J Phys
Condens Matter. 2006;18(38):2919-2934. doi:10.1088/0953-8984/18/38/S26

42.

Ward MA, Georgiou TK. Thermoresponsive polymers for biomedical applications.
Polymers (Basel). 2011;3(3):1215-1242. doi:10.3390/polym3031215

43.

Hu SH, Liu TY, Liu DM, Chen SY. Controlled pulsatile drug release from a

43

ferrogel by a high-frequency magnetic field. Macromolecules. 2007;40(19):67866788. doi:10.1021/ma0707584
44.

Brudno Y, Mooney DJ. On-demand drug delivery from local depots. J Control
Release. 2015;219:8-17. doi:10.1016/j.jconrel.2015.09.011

45.

Schild HG. Poly(N-isopropylacrylamide): experiment, theory and application.
Prog Polym Sci. 1992;17(2):163-249. doi:10.1016/0079-6700(92)90023-R

46.

Satarkar NS, Hilt JZ. Magnetic hydrogel nanocomposites for remote controlled
pulsatile

drug

release.

J

Control

Release.

2008;130(3):246-251.

doi:10.1016/j.jconrel.2008.06.008
47.

Hoare T, Santamaria J, Goya GF, et al. A magnetically-triggered composite
membrane for on-demand drug delivery. Nanoletters. 2011;9(10):3651-3657.
doi:10.1021/nl9018935.A

48.

Lu Z, Prouty MD, Quo Z, Golub VO, Kumar CSSR, Lvov YM. Magnetic switch
of

permeability

for

polyelectrolyte

microcapsules

embedded

with

Co@Aunanoparticles. Langmuir. 2005;21(5):2042-2050. doi:10.1021/la047629q
49.

Zhao X, Kim J, Cezar C a, et al. Active scaffolds for on-demand drug and cell
delivery.

Proc

Natl

Acad

Sci

U

S

A.

2011;108(1):67-72.

doi:10.1073/pnas.1007862108
50.

Cezar CA, Roche ET, Vandenburgh HH, Duda GN, Walsh CJ, Mooney DJ.
Biologic-free mechanically induced muscle regeneration. Proc Natl Acad Sci.
2016;113(6):1534-1539. doi:10.1073/pnas.1517517113

44

51.

Guowei D, Adriane K, Chen X, Jie C, Yinfeng L. PVP magnetic nanospheres:
Biocompatibility, in vitro and in vivo bleomycin release. Int J Pharm. 2007;328(1
SPEC. ISS.):78-85. doi:10.1016/j.ijpharm.2006.07.042

52.

Liu T-Y, Hu S, Liu T-Y, Liu D, Chen S. Magnetic-Sensitive Behavior of
Intelligent Ferrogels for Controlled Release of Drug. Langmuir. 2006;22(14):59745978. doi:10.1021/la060371e

53.

Hu SH, Liu TY, Liu DM, Chen SY. Nano-ferrosponges for controlled drug
release.

J

Control

Release.

2007;121(3):181-189.

doi:10.1016/j.jconrel.2007.06.002
54.

Qin J, Asempah I, Laurent S, Fornara A, Muller RN, Muhammed M. Injectable
superparamagnetic ferrogels for controlled release of hydrophobic drugs. Adv
Mater. 2009;21(13):1354-1357. doi:10.1002/adma.200800764

55.

Wang C, Seo SJ, Kim JS, et al. Intravitreal implantable magnetic micropump for
on-demand

VEGFR-targeted

drug

delivery.

J

Control

Release.

2018;283(May):105-112. doi:10.1016/j.jconrel.2018.05.030
56.

Pirmoradi FN, Jackson JK, Burt HM, Chiao M. On-demand controlled release of
docetaxel from a battery-less MEMS drug delivery device. Lab Chip.
2011;11(16):2744-2752. doi:10.1039/C1LC20134D

57.

Lee SH, Lee Y Bin, Kim BH, et al. Implantable batteryless device for on-demand
and pulsatile insulin administration. Nat Commun. 2017;8(May 2016):1-10.
doi:10.1038/ncomms15032

45

58.

Satarkar NS, Zach Hilt J. Hydrogel nanocomposites as remote-controlled
biomaterials. Acta Biomater. 2008;4(1):11-16. doi:10.1016/j.actbio.2007.07.009

59.

Papaphilippou P, Christodoulou M, Marinica OM, et al. Multiresponsive polymer
conetworks capable of responding to changes in pH, temperature, and magnetic
field: Synthesis, characterization, and evaluation of their ability for controlled
uptake and release of solutes. ACS Appl Mater Interfaces. 2012;4(4):2139-2147.
doi:10.1021/am300144w

60.

Liu TY, Hu SH, Liu KH, Liu DM, Chen SY. Study on controlled drug permeation
of magnetic-sensitive ferrogels: Effect of Fe3O4 and PVA. J Control Release.
2008;126(3):228-236. doi:10.1016/j.jconrel.2007.12.006

61.

Mehdaoui B, Meffre A, Carrey J, et al. Optimal size of nanoparticles for magnetic
hyperthermia: A combined theoretical and experimental study. Adv Funct Mater.
2011;21(23):4573-4581. doi:10.1002/adfm.201101243

62.

Jalili NA, Muscarello M, Gaharwar AK. Nanoengineered thermoresponsive
magnetic

hydrogels

for

biomedical

applications.

Bioeng

Transl

Med.

2016;1(3):297-305. doi:10.1002/btm2.10034
63.

Kennedy S, Roco C, Déléris A, et al. Improved magnetic regulation of delivery
profiles

from

ferrogels.

Biomaterials.

2018;161:179-189.

doi:10.1016/j.biomaterials.2018.01.049
64.

Satarkar NS, Hilt JZ. Magnetic hydrogel nanocomposites for remote controlled
pulsatile

drug

release.

J

Control

doi:10.1016/j.jconrel.2008.06.008
46

Release.

2008;130(3):246-251.

65.

Sato I, Umemura M, Mitsudo K, et al. Simultaneous hyperthermia-chemotherapy
with controlled drug delivery using single-drug nanoparticles. Sci Rep.
2016;6(April):1-12. doi:10.1038/srep24629

66.

Mertz D, Sandre O, Bégin-Colin S. Drug releasing nanoplatforms activated by
alternating magnetic fields. Biochim Biophys Acta - Gen Subj. 2017;1861(6):16171641. doi:10.1016/j.bbagen.2017.02.025

67.

Mormont MC, Levi F. Cancer chronotherapy: Principles, applications, and
perspectives. Cancer. 2003;97(1):155-169. doi:10.1002/cncr.11040

68.

Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual
growth

factor

delivery.

Nat

Biotech.

2001;19(11):1029-1034.

http://dx.doi.org/10.1038/nbt1101-1029.
69.

Brudno Y, Ennett-Shepard AB, Chen RR, Aizenberg M, Mooney DJ. Enhancing
microvascular formation and vessel maturation through temporal control over
multiple

pro-angiogenic

and

pro-maturation

factors.

Biomaterials.

2013;34(36):9201-9209. doi:10.1016/j.biomaterials.2013.08.007
70.

Mehta M, Schmidt-bleek K, Duda GN, Mooney DJ. Biomaterial delivery of
morphogens to mimic the natural healing cascade in bone ☆. Adv Drug Deliv Rev.
2012;64(12):1257-1276. doi:10.1016/j.addr.2012.05.006

71.

Mormont MC, Lévi F. Circadian-system alterations during cancer processes: A
review.

Int

J

Cancer.

1997;70(2):241-247.

0215(19970117)70:2<241::AID-IJC16>3.0.CO;2-L

47

doi:10.1002/(SICI)1097-

72.

Ratner BD, Hoffman AS, Schoen FJ, Lemons JE. Application of Biomaterials:
Implants and Inserts. In Biomaterials Science: An Introduction to Materials in
Medicine. In: Ratner BD, Hoffman AS, Schoen FJ, Lemons JEBT-BS (Third E,
eds.

Academic

Press.

Waltham,

MA.;

2013:1062-1068.

doi:https://doi.org/10.1016/B978-0-08-087780-8.00153-4
73.

Cara S, Tannock IF. Retreatment of patients with the same chemotherapy:
Implications

for

clinical

mechanisms

of

drug

resistance.

Ann

Oncol.

2001;12(1):23-27. doi:10.1023/A:1008389706725
74.

Goldman A, Majumder B, Dhawan A, et al. Temporally sequenced anticancer
drugs overcome adaptive resistance by targeting a vulnerable chemotherapyinduced

phenotypic

transition.

Nat

Commun.

2015;6:1-13.

doi:10.1038/ncomms7139
75.

Emi T, Barnes T, Orton E, et al. Pulsatile Chemotherapeutic Delivery Profiles
Using Magnetically Responsive Hydrogels. ACS Biomater Sci Eng. 2018.
doi:10.1021/acsbiomaterials.8b00348

76.

Tolouei AE, Dülger N, Ghatee R, Kennedy S. A Magnetically Responsive
Biomaterial System for Flexibly Regulating the Duration between Pro- and AntiInflammatory

Cytokine

Deliveries.

Adv

doi:10.1002/adhm.201800227

48

Healthc

Mater.

2018;7(12).

Chapter 3

Manuscript (I): A magnetically responsive biomaterial system for
flexibly regulating the duration between pro- and antiinflammatory cytokine deliveries

Published in the Advanced Healthcare Materials Journal, April 2018

By Anita E. Tolouei, Nihan Dülger, Rosa Ghatee, Stephen Kennedy*
Department of Chemical Engineering,
University of Rhode Island, Kingston, Rhode Island 02881

* Corresponding author: Stephen Kennedy
Email: smkennedy@uri.edu,
Phone: (401) 874-5295,
Fax: (401) 782-6422

49

3.1

Abstract
While inflammation can be problematic, it is nonetheless necessary for proper

tissue regeneration. However, it remains unclear how the magnitude and duration of the
inflammatory response impacts regenerative outcome. This is partially due to the
difficulty in temporally regulating macrophage phenotype at wound sites. Here, a
magnetically responsive biomaterial system potentially capable of temporally regulating
macrophage phenotypes through sequential, on-demand cytokine deliveries is presented.
This material system is designed to (i) rapidly recruit proinflammatory macrophages
(M1) through initial cytokine deliveries and (ii) subsequently transition macrophages
toward anti-inflammatory phenotypes (M2s) through delayed, magnetically triggered
cytokine release. Here, the ability of this system to initially deliver proinflammatory
cytokines (i.e., monocyte chemoattractant protein-1 and interferon gamma), recruit, and
harbor an expanding macrophage population, and delay deliveries of anti-inflammatory
cytokines (i.e., IL-4 and IL-10) until the application of magnetic fields from simple handheld magnets is demonstrated. Critically, the timing and rate of these delayed deliveries
can be remotely/magnetically controlled. This biomaterial system can provide a powerful
tool in (i) understanding the relationship between inflammation and regenerative outcome,
(ii) developing optimized cytokine delivery strategies, and (iii) clinically implementing
those optimized delivery strategies with the on-demand versatility needed to alter the
course of therapies in real time.
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3.2

Introduction
It has been estimated that 1 to 2% of the population in developed countries will

experience a chronic wound over their lifespan.[1] Occurrence of chronic wounds are
particularly common in growing elderly populations and those who are suffering from
diabetes and obesity.[2] While there are several phases in wound healing (i.e., coagulation,
inflammation, proliferation, and remodeling),[3–6] chronic wounds are typically the result
of prolonged and/or uncontrolled inflammation.[2,7] Despite this, inflammation is an
indispensable step in the wound healing process and sets the stage for proper regeneration
by staving off infection, clearing the wound site of debris, and recruiting cells to the
wound that play critical roles in tissue remodeling and re-vascularization.[3,6,8,9] In fact,
studies have shown that suppressing the inflammatory response actually hinders proper
wound healing.[4,10] Macrophages play a key role in regulating the inflammatory response
and in directing the transition to later stages of the wound healing process. [11–17] We and
others believe that regulating the time at which macrophages transition from coordinating
an inflammatory response (Figure 1.a, Phase 1 (red)) to coordinating later pro-healing
stages of the wound healing process (Phase 2 (blue)) may be key to understanding the
role of inflammation in wound healing and in developing improved treatment
strategies.[18–20] For example, it is apparent that proper healing requires an inflammatory
phase that eventually transitions into anti-inflammatory, pro-healing phases.[21,22]
However, it remains unknown how the duration of this inflammatory phase (Tih) impacts
or can be used to optimize wound healing outcome. Moreover, optimal durations are
likely different for different wounds and for different patients. This motivates the need
for biomaterials that enable flexible control over the duration of this inflammatory period,
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as both an investigative and clinical tool.
Here, we propose a biomaterial system designed to deliver immunomodulatory
cytokines in a manner that can potentially regulate the inflammatory period’s duration in
a flexible and on-demand manner. The inflammation phase can be initiated by
establishing a population of pro-inflammatory M1 macrophages through the delivery of
proteins that recruit macrophages and polarize them towards M1 phenotypes (Figure 1.b,
M0 to M1): for example, Monocyte Chemoattractant Protein-1 (MCP-1),[23,24] and
Interferon Gamma (IFN-γ).[25] Transition from inflammatory to healing phases requires
establishing a population of anti-inflammatory M2 macrophages (e.g., alternatively
activated M2a, Mb, and Mc phenotypes). This can be triggered through the delivery of
other proteins at the wound site: for example, Interleukin-4 (IL-4),[26,27] and Interleukin10 (IL-10),[26,27] (Figure 1.b, M0/M1 to M2).
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Figure 0.1. Regulating the inflammatory period requires initial delivery of pro-inflammatory
cytokines followed by delayed delivery of anti-inflammatory cytokines. (a) Schematic describing
the cytokines that regulate the inflammation phase (I, red) and healing phase (II, blue). (b)
Schematic describing how M0 macrophages can be polarized into M1 (Pro-inflammatory) and/or
M2 (Anti-inflammatory) phenotypes when exposed to different cytokines. (c) Illustration of the
desired cumulative release profile: initial release of macrophage recruitment and proinflammation cytokines (red), followed by delivery of anti-inflammatory cytokines (blue). (d)
Illustration of the proposed biomaterial system (top) with illustration key (bottom).

Thus, it may be possible to regulate the duration of the inflammatory response
(Tih) through initial deliveries of pro-inflammatory cytokines, such as MCP-1 and IFN-γ
(Figure 1.c, red curve), followed by delayed deliveries of anti-inflammatory cytokines,
such as IL-4 and/or IL-10 (Figure 1.c, blue curve). Here, we will describe a twocompartment biomaterial system (Figure 1.d) designed to: (i) initially release proinflammatory cytokines from an outer compartment for the recruitment and establishment
of pro-inflammatory macrophage phenotypes, (ii) allow for an inflammatory period to
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continue until, (iii) a magnetic gradient is applied that deforms the inner compartment,
releasing anti-inflammatory cytokines, which would (iv) direct macrophages to take on
pro-healing phenotypes. Such a material system could enable control over the
inflammatory period’s duration simply by applying a magnetic gradient (from simple
hand-held magnets or electromagnets) at the time point at which one wishes
inflammation to transition into an anti-inflammatory phase.

3.3

Materials and methods

3.3.1

Fabrication and imaging of the biomaterial system
The outer compartment gelatin scaffolds used in these studies were purchased as 2

x 12 x 7 mm GelFoam™ sponge sheets (Pfizer, Groton, CT) and cut into hollow disks (2mm tall, 8-mm OD, 4-mm ID) using 8-mm and 4-mm biopsy punches. Note that biopsy
punches and GelFoam sponges were packaged sterile for cell experiments. Additionally,
they were packaged in lyophilized form, allowing them to be sputter-coated (30 seconds
in gold) and imaged under Scanning Electron Microscopy (SEM) on a Zeiss SIGMA VP
Field

Emission-SEM

with

cryogenic

capability and

Energy-dispersive

X-ray

Spectroscopy (EDS) for elemental mapping.
The inner ferrogel compartments were made similarly to those described in Cezar
et al.[28] Briefly, alginate was dissolved in MES buffer (100 mM MES and 500 mM NaCl
at pH = 6.0) containing HOBT and AAD crosslinker and was cast with iron oxide
particles and EDC (100 mg mL-1) between two Sigmacote-treated glass plates that were
separated by 2-mm spacers. During casting (~ 1 hour), a magnet was placed against one
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glass plate as to pull the iron oxide particles towards one side of the gel, yielding a
biphasic structure. Individual biphasic ferrogels were cut into 4 x 2 mm disks using a
biopsy punch and then washed in 50 mL deionized water for 3 days (with water being
exchanged twice a day) so that they would fully swell and become void of residual
reagents. Ferrogels were then frozen at -20 ºC overnight and lyophilized. Lyophilized
ferrogels were prepared for imaging by cross sectioning them using a sharp razor, sputtercoating in gold, and imaging as described above for the outer gelatin scaffolds.
3.3.2

Macrophage recruitment studies
In their culture flasks, RAW 264.7 mouse macrophages were rinsed in PBS,

resuspended in fresh DMEM, scraped off, collected, and plated at 10,000 cells per well
on sterile 12-well plates. Macrophages were submerged in serum-containing DMEM and
allowed to grow for 24 hours. A sterile gelatin scaffold (cut into a hollow disk) was then
placed on top of the 2D culture in well plates (fully submerged in media) and left to
recruit macrophages for 10 days. Macrophage-populated gelatin scaffolds were analyzed
by fixing them in 4% PFA for 10 minutes and washed for 5 minutes in PBS, 3 times.
Scaffolds were then soaked in a 0.2% Triton X-100/PBS solution for 5 minutes to
permeabilize cell membranes, then washed for 5 minutes in fresh PBS, 3 times.
Macrophage nuclei were DAPI-stained by soaking scaffolds in a 2 μg/mL solution of
DAPI in PBS for 5 minutes and then washing for 5 minutes in fresh PBS, 3 times. Finally,
macrophage actin cytoskeletons were stained by soaking scaffolds in a 0.5 μg/mL
solution of FITC-phalloidin in PBS for 5 minutes and then washing for 5 minutes in fresh
PBS, 3 times.
3D fluorescent image reconstructions were obtained by taking a green/blue
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confocal slice every 10 μm from the bottom of the scaffold to a depth of 170 μm within
the scaffold using a Nikon TE2000E inverted confocal microscope and its associated
NIS-Elements software package. Macrophage cell density counts were taken by inverting
the gels in a fresh 12-well plate so that the top of the gels faced down against the plate.
Well plates were then loaded into a BioTek Cytation 3 Cell Imaging Multi-Mode Reader
which was set to capture a blue-channel image 200 μg into the scaffold (which was 1800
μm away from the side of the scaffold originally near the 2D macrophage culture).
BioTek Gen5 software was used to quantify DAPI-nuclei count from these blue-channel
images.
3.3.3

Magnetic stimulation of ferrogels
Ferrogels were magnetically stimulated using 0.5” x 0.5” x 0.5” (1.32 x 1.32 x

1.32 cm) cylindrical neodymium magnets (K&J Magnetics, Pipersville, PA) that were
integrated into a custom stimulation apparatus that enabled repetitive and prolonged
magnetic field exposures. The custom stimulation apparatus consisted of an array of
cylindrical neodymium magnets place on the teetering edge of a variable-speed
laboratory rocker’s platform (4 magnets on one edge and 4 on the opposite edge, see
MovieS2 in supporting information). This arrangement allowed 8 magnets to oscillate up
and down (proximally and distally to 8 ferrogel samples) at a rate prescribed by the
rocker’s speed. These studies all utilized the maximum rate of 1.4 Hz (i.e., one magnetic
compression every 0.71 seconds). Ferrogels were placed in Sigmacote-treated
scintillation vials and suspended above our custom stimulation apparatus with aluminum
clamps. This arrangement allowed ferrogel samples to be in close proximity to the
magnetics when the magnets were raised (though the magnets did not physically touch
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the vials) and far enough away from the magnets (~10 cm) when the magnets were
lowered, allowing the ferrogels to fully compress and conform back to their original uncompressed thickness between each cycle.
3.3.4

Cytokine time course release studies
Outer compartment gelatin scaffolds were unpacked and punched to shape in a

lyophilized state. Thus, to load them with cytokine, concentrated solutions of protein
were prepared and added dropwise directly to the dehydrated scaffolds. It was determined
beforehand that when adding liquid to these scaffolds in this manner, they could fully
absorb no more than 40 μL of solution. Thus, when loading the scaffolds, concentrated
solutions were prepared such that the desired amount of protein to be loaded in the
scaffold be contained in 40 μL volumes (e.g., 1000 ng MCP-1 loading required
preparation of a concentrated solution of 1000 ng MCP-1 in 40 μL of PBS). So, scaffolds
were placed in Sigmacote-treated scintillation vials (to limit protein adsorption to the
surfaces of the vials) and loaded dropwise with concentrated protein solutions (MCP-1 or
IFN-γ, prepared at concentrations as described above). Scintillation vials were then
capped and the scaffolds were left overnight at room temperature to fully absorb the
protein. Time-course release studies began after overnight protein absorption when
scaffolds were submerged in 1 mL PBS with 1% BSA (t = 0). 1 mL samples were
collected periodically from the vials and reserved for analysis by freezing in 1.5 mL
centrifuge tubes. After sample removal, fresh 1 mL of PBS with 1% BSA was gently
added back to the vial until the next sample was taken. After all samples were collected
(168 hours), they were thawed and quantified for cytokine content using ELISA.
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Release studies from ferrogels followed a similar procedure. As described above,
ferrogels were prepared with the final step being lyophilization, thus producing
macroporous and dehydrated samples. Dried ferrogels were placed in scintillation vials
with the Fe3O4-free region facing up. It was determined beforehand that when adding
liquid to these ferrogels that they could fully absorb no more than 20 μL of solution.
They were therefore loaded using desired weights of protein dissolved in 20 μL of PBS
(e.g., 1000 ng IL-4 in 20 μL PBS). Ferrogels were left to absorb the protein overnight in
capped vials. Ferrogels were then rinsed in PBS with 1% BSA for 3 days to remove
excess unincorporated protein, which reduced unstimulated baseline release. Ferrogels
were then periodically sampled as described with the gelatin scaffolds, with sample
media being fully removed and replaced with fresh media at each timepoint. Collected
samples were quantitatively analyzed for IL-4 or IL-10 release using ELISA.
3.3.5

Statistical analyses
All quantitative data presented in this communication are represented as a mean ±

standard deviation with 4 replicates (N = 4).

Because only one-to-one statistical

comparisons were made in this study (i.e., no multiple comparisons), student t-tests (twotailed distributions, heteroscedastic) were used to calculate p-values with p < 0.05 being
our benchmark for significance (Microsoft Excel).

3.4

Results and discussion
This two-compartment biomaterial system comprises an outer gelatin scaffold and

an inner biphasic ferrogel (Figure 2.a). The outer compartment exhibited an
interconnected macroporous structure designed to permit rapid cell infiltration (Figure
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2b). Also, by virtue of being made from gelatin (a hydrolyzed form of collagen), this
gelatin scaffold presents binding motifs for cell binding, motility, and spreading.[28,29] For
the inner compartment, we utilized a biphasic ferrogel with an Fe3O4-laden region on the
top half of the cylindrical gel and an Fe3O4-free, porous, and deformable region on the
bottom (Figure 2.c).

(a)

Complete system

Comp. 1

Comp. 2

(b) i

(c) i
5 mm
2 mm

ii

ii
Fe
C

5 mm

elemental map

200 mm

Figure 0.2. Two-compartment biomaterial system comprises a magnetically responsive biphasic
ferrogel nested within an outer macroporous gelatin scaffold. (a) Photographs of the 2compartment biomaterial system at an angle (top) and from the top (bottom). (b) Cross-sectional
photograph (i) and SEM micrographs (ii) of the outer porous gelatin compartment. (b) Crosssectional photograph (i) and SEM microgarphs (ii) of the inner biphasic ferrogel compartment.
Elemental map reveals the location of iron (red) and carbon (yellow-green).
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Figure 0.3. The outer macroporous gelatin scaffold can recruit and harbor macrophages and can
rapidly release pro-inflammatory cytokines. (a) Schematic detailing how macrophages were
recruited to the gelatin scaffold and where in the scaffold different images and measurements
were taken. (b) Left: 3D z-stack detailing DAPI- (blue) and Phalloidin- (green) stained
macrophages in the bottom 170 μm of the scaffold on day 5. Right: collage image of DAPIstained macrophages (blue) taken 1800 μm from the bottom of the gel (200 μm from the top). (c)
Quantification of macrophage density vs. time recorded 1800 microns from the bottom of the
scaffold. (d) Cumulative release vs. time for scaffolds loaded with 1000 ng (solid) and 100 ng
(dashed) of MCP-1. (e) Cumulative release vs. time for scaffolds loaded with 1000 ng (solid) and
100 ng (dashed) of IFN-γ. Inset: zoomed-in cumulative release vs. time for scaffold loaded with
100 ng IFN-γ. Parts (c)-(e), N = 4.

These biphasic ferrogels were designed to efficiently deform in the presence of a
graded magnetic field (i.e., in the presence of fields emanating from simple hand-held
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magnets or electromagnets). When magnetically deformed, these gels would release
molecular payloads stored in the Fe3O4-free region in a magnetically triggered manner.
The particular ferrogel formulation adopted here (1 wt% alginate, 7 wt% Fe3O4, 2.5 mM
adipic acid dihydrazide cross-linked, freeze-dried at -20ºC) was previously shown to be
optimal in terms of providing magnetically triggered deliveries.[30,31]
The outer porous gelatin scaffold was designed to provide initial deliveries of proinflammatory cytokines and to recruit and permit the residence of macrophages. To test
this compartment’s ability to recruit and establish macrophage populations, RAW 264.7
macrophages were seeded at 10,000 cells per well in a 12-well plate on Day -1 and
allowed to establish themselves for 24 hours as a 2-dimensional (2D) colony. Then (at
Day 0), gelatin scaffolds (compartment 1, Figure 2.b) were placed on top of 2D
macrophage colonies and left for 10 days so that macrophages could infiltrate the volume
of the scaffold (Figure 3a). On Day 5, some scaffolds were removed, fixed, and stained
for f-actin (FITC-Phalloidin) and nuclei (DAPI), revealing that macrophages had
infiltrated and spread within the bottom volume of the gel (Figure 3.b (left) and
MovieS1.mov in Supporting Information). Also, by Day 5, some Macrophages had
reached the top of the gel (Figure 3.b (right))). DAPI-stained macrophages residing 1800
μm from the bottom of the gel (i.e., 200 μm from the top of the 2-mm gel) were
quantified using fluorescence microscopy on days 5 and 10 (Figure 3.c). This
demonstrated that the macrophage populations could establish themselves and increase in
population through the volume of these scaffolds over the course of 10 days in vitro. It
must be noted that these in vitro studies utilized RAW macrophages which are more
proliferative than the native macrophages that would be recruited to this material in vivo.
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Thus, there is no way of knowing if macrophage population increase vs. time is due to
migration through the material, proliferation, or some combination thereof. Additionally,
the cell densities vs. time observed here (Figure 3.c) are likely higher than what would be
expected in vivo. However, to enhance macrophage populations, these scaffolds could
also be loaded with cytokines that could potentially expedite macrophage recruitment, as
well as polarize them towards M1 phenotypes at early timepoints after implantation (e.g.,
MCP-1 and IFN-γ, respectively). These cytokines released rapidly at early time points
(Figure 3.d & 3.e) due to excess cytokine being added to the outer compartment without
rinsing off that excess cytokine prior to use. The total amount of cytokine delivered could
be dictated simply by loading the scaffold with more or less cytokine (Figure 3.d & 3.e,
comparing solid and dashed curves). Independent of loading, pro-inflammatory cytokine
release ceased after roughly 12 hours (Figure S1), well before the times at which
magnetic stimulation would be applied to trigger subsequent deliveries of antiinflammatory cytokines.
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Figure 0.4. The inner ferrogel compartment can produce delayed, magnetically triggered antiinflammatory cytokine delivery profiles. (a) Illustration (left) and photographs (right) of a
biphasic ferrogel before (top) and during (bottom) magnetic compression. (b) Schematics of the
two magnetic stimulation profiles used in these studies: (top, green) a cyclic magnetic field of 1.4
compressions per second continuously over 3 hours and (bottom, red) the same exposure but
pulsed so that gels are cyclically compressed for 5 minutes every hour. (c) Amount released after
3 hours of stimulation profile A (green) vs. B (red). (d) Cumulative IL-4 release vs. time from
ferrogels that were either magnetically stimulated on day 3 (dashed) or day 5 (solid). (e)
Cumulative IL-10 release vs. time from ferrogels that were magnetically stimulated on days 4, 5,
and 6. (f) Release rates over the indicated times when magnetically stimulated (red) vs.
unstimulated (gray). For parts (c)-(f), ** and *** indicate statistically significant differences with
p < 0.01 and 0.001, respectively (N = 4).

The inner compartment of this biomaterial system (Figure 2.c) was designed to
provide delayed, on-demand, and magnetically triggered delivery of anti-inflammatory
cytokines (e.g., IL-4 and IL-10). These biphasic ferrogels were designed so that cytokines
could be loaded in their Fe3O4-free regions and released in earnest when magnetic
gradients were used to compress the Fe3O4-free regions (Figure 4.a, white region of
ferrogel compresses when a hand-held magnetic is subjacently applied). See
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MovieS2.mov in Supporting Information for a movie of a biphasic ferrogel being
magnetically compressed repeatedly at 1.4 Hz. Cytokine release rates prior to magnetic
stimulation were kept at low levels by thoroughly rinsing ferrogels, as to remove excess
cytokines that were not well-incorporated. Additionally, cytokine retention prior to
magnetic stimulation was likely aided by the use of alginate as the polymeric constituent
of these ferrogels. Alginate is heparin-mimicking, and heparin is known to bind strongly
to a wide variety of cell-secreted proteins. In these studies, magnetic gradients were
applied over the course of 3 hours, but with different temporal profiles (Figure 4.b): (i)
one where a magnetic gradient was applied at a rate of 1.4 Hz continuously over 3 hours
(Stimulation Profile A, top, green) and (ii) one where a magnetic gradient was applied at
a rate of 1.4 Hz intermittently, lasting for 5 minutes every hour for 3 hours (Stimulation
Profile B, bottom, red). The intermittent Profile B actually yielded higher rates of
cytokine delivery compared to the continuous Profile A (Figure 4c). This is possibly due
to the fact that magnetic compression results in release of molecules primarily contained
in the macropore space and not contained in the gel’s matrix (note that the Fe3O4-free
region of these ferrogels are highly macroporous (Figure 2.c)). Thus, continuous 1.4 Hz
stimulation (Profile A) may initially purge these more available molecules from the pore
space but may prohibit the molecules in the gel from equilibrating (i.e., molecules that
were purged from the macropore space cannot be replaced by molecules contained in the
matrix space due to constant 1.4 Hz gel compression). This would result in a relatively
low rate of release when averaged over 3 hours. However, intermittent stimulation (i.e.,
Stimulation Profile B) likely permits this re-equilibrium of molecules in the 1 hour
between subsequent magnetic compressions, resulting in a distribution of molecules from
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the matrix to the pore space. When magnetic stimulation continues, these relocated porespace-molecules are efficiently purged. This may result in higher release rates when
averaged over 3 hours. While these dynamics are outside the scope of this study,
Stimulation Profile B has significant practical advantages in that it both produces higher
rates of release and would be easier to implement in vivo. That is, 5 minutes of 1.4 Hz
stimulation every hour can be implemented by manually brining a hand-held magnet
close to the implant site whereas 3 hours of continuous 1.4 Hz stimulation could be tiring
if performed manually. Nevertheless, neither magnetic stimulation profile resulted in
statistically significant changes in gel mechanics (Figure S2), suggesting that magnetic
stimulation does not overly damage the gels. This leaves open the possibility of
magnetically stimulating at later time points for subsequent release busts.
Even though, Stimulation Profile A produced lower rates of release than
Stimulation Profile B, it was nonetheless sufficient to significantly impact an antiinflammatory cytokine’s release profile. When loaded with 500 ng of IL-10, ferrogels
released baseline levels of IL-10 prior to day 3 but dramatically increased release rates on
day 3 when stimulated using Magnetic Stimulation Profile A (Figure 4.d, dashed curve).
If this delayed IL-10 release was desired on day 5 rather than 3, magnetic stimulation
could be applied on day 5 rather than day 3 (Figure 4.d, solid curve). This ability to
control the time at which anti-inflammatories are earnestly released could provide a
powerful tool for investigating how the duration of the inflammatory response impacts
wound healing outcome. Magnetic stimulation can also potentially be used to repetitively
deliver anti-inflammatory cytokines on subsequent days to prevent an inflammatory
response from resurging. For example, when loaded with 1000 ng of IL-4, baseline levels
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of IL-4 were released prior to magnetic stimulation. But, release rates were dramatically
enhanced when stimulated on day 4 using Stimulation Profile B (Figure 4.e, compare
slope of curve before 96 hours to the slope from 96 to 99 hours). The rate of IL-4 release
could be subsequently enhanced on days 5 and 6 when magnetically stimulated on those
days (Figure 4.e, enhanced slopes at 120 and 144 hours). These magnetically stimulated
release rates on days 4, 5, and 6 were significantly higher than control gels upon which
no magnetic stimulation was applied (Figure 4.f). These studies demonstrate our ability to
control the timing and rate of these anti-inflammatory cytokine deliveries in an ondemand, magnetically prescribed manner.
The described biomaterial system could improve control over the inflammatory
response in wound healing applications by locally regulating macrophage phenotype
through carefully timed immunomodulatory cytokine deliveries. There is a growing
preponderance of evidence suggesting that regulating macrophage phenotype vs. time is
critical to achieving desired outcomes in wound healing and regenerative therapies,[32–36]
and that sequenced deliveries of immunomodulatory cytokines can provide a means for
this temporal regulation.[26,37] In fact, previous studies have designed scaffolding
materials to release pro- and anti-inflammatory cytokines at different rates in an attempt
to temporally control macrophage phenotype.[19,38–41] While these studies yielded
promising results in their ability to influence macrophage phenotype in vivo, statistically
significant improvements in regeneration were not observed (e.g., larger or more wellorganized vessels/tissues). This could have been due to the inability to explicitly alter and
optimize the timing of different cytokine deliveries (i.e., having the delay time of antiinflammatory cytokines be a variable parameter between conditions). The biomaterial
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system described here could enable explicit control over the timing of these deliveries,
without having to alter the chemistry or structure of the implantable scaffold material
between experiments. It should be noted, however, that with this material system’s
current formulation, macrophages initially recruited to the outer compartment may be
exposed to baseline levels of anti-inflammatory cytokines diffusing out of the inner
ferrogel (Figure. 4.d & 4e, IL-10 and IL-4 release is non-zero prior to magnetic
stimulation). Even though magnetically stimulated release is significantly higher than
diffusive release (Figure 4.d & 4.e, comparing slopes of curves with and without
magnetic stimulation), if diffusive release establishes a bioactive concentration of antiinflammatory cytokines, macrophages may begin to polarize towards pro-healing
phenotypes prior to magnetic stimulation. Thus, fine-tuning of the biomaterial system
will be required so that rates of release prior to magnetic stimulation result in subbioactive anti-inflammatory cytokine concentrations and release rates during magnetic
stimulation result in bioactive concentrations. Such fine tuning can be achieved by
modifying cytokine loading and ferrogel formulation (e.g., porosity, polymer
concentration, polymer type, crosslinking density). Such a tuned biomaterial system will
need to be tested in order to verify that this material system is capable of temporally
regulating macrophage phenotype through magnetic stimulation.
In sum, we have developed a biomaterial system capable of initially delivering
pro-inflammatory cytokines (MCP-1 and IFN-γ) from a macroporous gelatin structure
capable of facilitating macrophage infiltration and growth. The amount of inflammatory
cytokine release was dependent on the amount of cytokine loaded in the structure. This
biomaterial system was also integrated with a biphasic ferrogel that was capable of
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delivering anti-inflammatory cytokines (IL-4 and IL-10) in a delayed and magnetically
triggered manner, using common hand-held magnets. The rate of magnetically stimulated
delivery could be regulated by using different magnetic stimulation profiles and the
timing of delivery could be regulated simply by choosing when to apply magnetic
stimulation. This biomaterial system thus has the potential to enable experimental
investigations into how the rate and timing of pro- and anti-inflammatory cytokine
deliveries impact biological process critical in wound healing applications. Finally, this
material system could also provide the material means to therapeutically implement
optimized sequential cytokine deliveries, while retaining a high degree of clinical
adaptability by enabling real-time alterations in delivery profiles.

Supporting Information: Appendix A
Additional experimental details and supplemental figures are provided in
Supporting Information in Appendix A.
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4.1

Abstract
Sequential protein release is required in regulating many biological processes that

underlie injury and disease. A magnetically responsive dual-compartment biomaterial
was therefore designed and successfully applied to provide on-demand sequential release
of proteins relevant to specific therapies that would benefit from sequential release. The
composition of this biomaterial system consists of a gelatin outer compartment and a
ferrogel inner compartment. Three pairs of relevant proteins were incorporated in the
biomaterial system: (1) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF,
a dendritic cell recruitment factor) and Heat Shock Protein 27 (HSP27, as a model cancer
antigen) for use in cancer immunotherapy; (2) Vascular Endothelial Growth Factor
(VEGF, an angiogenic sprouting factor) and Platelet Derived Growth Factor (PDGF, a
factor that aids in maturing vascular sprouts) for tissue vascularization; and, (3) Stromal
cell Derived Factor-1α (SDF-1α, a bone progenitor cell recruitment factor) and bone
morphogenetic protein 2 (BMP2, a osteo-differentiation factor) for bone regeneration. It
was demonstrated that proteins loaded in the outer compartment (GM-CSF, VEGF, SDF1α) released rapidly within the first 24 to 100 hours and that the amount released was
dependent on how much protein was loaded in the compartment. timing and rate of
release of these proteins can be controlled via magnetic stimulation. Proteins loaded in
the inner ferrogel (HSP27, PDGF, BMP2) could be magnetically triggered to provide
delayed enhancements in release rate where the timing (between days 1 and 8) and rate of
release (0.2 to 1 ng/hr) were externally controlled through the temporal profile of magnet
application and the frequency of that application. This biomaterial system can be used to
investigate how the timing and sequence of protein deliveries impacts the biological
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processes that underlie cancer immunotherapy, tissue vascularization, and bone
regeneration (and potentially in many other therapeutic areas) and can be used to
experimentally optimize deliveries in these therapies.

4.2

Introduction
Hydrogels have been commonly used as biomaterials in drug delivery and tissue

engineering applications due to their biocompatibility and versatility. 1–3 These drug
delivery materials can potentially control important biological processes that need to be
regulated to treat injury and disease. However, most biologies are sequential in nature
and require sequential presentations of bio-instructive factors for proper regulation. For
example, cancer is the second most common cause of death in the United States and
accounts for nearly 1 of every 4 deaths.4 This emphasizes the necessity of finding
effective cancer treatment strategies. One promising cancer treatment strategy is
biomaterials-based immunotherapy in which the immune system of the patient’s own
body is reprogramed in order to initiate an immunological attack against cancer cells.5–7
In this approach, first, dendritic cells (DCs) need to be recruited to the biomaterial by
releasing a DC recruitment factor (Factor I) (Fig 1.A.i, ii). Once a large number of DCs
are resident in the biomaterial (Fig 1.A.iii), they can become activated when presented
with a cancer antigen (Factor II) (Fig 1.A.iv). Activated DCs would then migrate out of
the biomaterial towards lymph node (Fig 1.A.v), triggering an immunological attack
against cancer. Therefore, sequential release of recruitment factor followed by release of
activating factor could potentially improve control over regulating the biological
processes pertinent to biomaterial-based cancer immunotherapies.
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Beyond cancer treatments, regulation of vascular growth can be of great potential in
the treatment of different cardiovascular diseases (CVDs), which are the most common
cause of death in the United States and worldwide.8 It has been reported that CVD was
the main cause of more than 50% of deaths in 2010.9 Additionally, regeneration of tissues
after surgery or injury often involves regulating the growth of new vascular networks.10–
12

Pericyte cells play a key role in vessel formation and presentation of several growth

factors can regulate this process.13 For example, growth of new blood vessels can be
initiated by an initial presentation of angiogenic factors (Factor I) which instructs pericyte
cells to detach from the endothelium of nearby vasculature. This detachment destabilizes
the endothelium and allows small vascular sprouts to grow away from the existing blood
vessel (Fig 1.B.i, ii). These nascent sprouts are thin, unorganized, and not mature enough
to efficiently perfuse blood through them (Fig 1.B.iii). Hence, an additional maturation
factor (Factor II) is subsequently released to recruit pericyte cells back to neovessels (Fig
1.B.iv), which in turn helps neovessels mature into a thicker and more interconnected
network (Fig 1.B.v).
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Figure 0.1. Sequential delivery of multiple factors is essential for improved outcome in multiple
therapies. A) Schematic showing how sequenced deliveries could be beneficial for biomaterialbased cancer immunotherapy B) tissue vascularization and C) bone regeneration.

Finally, sequential delivery of bio-instructive factors can be of potential value in
regenerating bone tissues. Each year more than 6 million bone fractures occur in the
United States, leading to approximately 900,000 patient hospitalizations.14 Biomaterial
scaffolds can be promising substitutes for traditional autogenic and allogenic grafting
since they can decrease the problems associated with donor site sensitivity, morbidity,
and limited availability of these grafts.15,16 Bone regeneration also is naturally regulated
by a sequence of growth factor presentations.17 First, osteoprogenitor cells need to be
recruited to the scaffold by releasing a bone progenitor recruitment factor (Factor I) (Fig
1.C.i, ii). After establishing a population of these progenitor cells in the biomaterial (Fig
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1.C.iii), they can be differentiated down the osteogenic lineage by exposing them to a
osteo-differentiation factor (Factor II) (Fig 1.C.iv). Differentiated bone cells would then
start secreting their own robust bone matrix, which is a vital step in regenerating new
bone tissues (Fig 1.C.v).Therefore, in order to better regulate these regenerative
processes, sequential delivery of bone progenitor recruitment and differentiation factors
is necessary.
In previous studies, hydrogels were demonstrated to have sequentially protein
release capabilities using formulations containing phases with different degradation rates.
However, the timing between these two deliveries was not capable of being regulated
after implantation or injection of these biomaterials.18–20 Additionally, these delivery
profiles can more aptly be described as dual deliveries with different rates and not
sequential release per se (i.e., on burst release followed by a second, delayed burst
release). The biomaterial system presented here was specifically designed to provide
sequential delivery profiles where there is an initial burst release of one factor followed
by a magnetically triggered, delayed release of a second factor. This was achieved by
composing the biomaterial with two compartments (Fig 2.A.i, ii). Compartment 1,
initially releases Factor I and has a functionality to maintain recruited cells (Fig 2.A.iii,
iv). Compartment 2 is capable of releasing Factor II in an on-demand manner when
remotely stimulated with a magnetic field (Fig 2.A.v). This study aimed to demonstrate
the ability to generate these sequential delivery profiles for specific recruitment factors
(GM-CSF, VEGF, SDF-1α) followed by magnetically triggered delivery of programming
factors (HSP27, PDGF, BMP2) (Figure 2.B), which are relevant to regulating sequential

81

biologies in cancer immunotherapy, generation of new vascular networks, and in
regenerating bone tissues, respectively (Fig 2.C).
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Figure 0.2. New Biomaterial system is designed to improve sequential delivery of several factors
in an on-demand manner. A) Schematic of the multi-compartment biomaterial system shows how
delivery of multiple factors can be accomplished in a controlled sequenced manner B) Desired
cumulative release of factor I and II. C) Table shows different therapies and factors mediating
these processes.

4.3

Materials and methods

4.3.1

Materials
High guluronate content sodium alginate (Protonal LF 20/40) with molecular

weight of ~ 250 kDa was provided by Pronova Biopolymers (Olso, Norway). Other
chemicals such as Adipic Acid Dihydrazide (AAD), 1-ethyl-3-(dimethylaminopropyl)
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carbodiimide (EDC), compound 2-(N-morpholino)ethanesulfonic acid (MES), 1hydroxybenzotriazole (HOBt), iron (II,III) oxide powder (< 5 micron), Phosphate
Buffered Saline (PBS), Sigmacote®, and Bovine Serum Albumin (BSA) were all
purchased from Sigma-Aldrich (St. Louis, MO). Granulocyte Macrophage Colony
Stimulating Factor (GM-CSF), Heat shock Protein 27 (HSP27), Vascular Endothelial
Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Stromal Cell-derived
Factor 1-α (SDF-1α), Bone Morphogenetic Protein 2, and all Enzyme-linked
Immunosorbent Assay (ELISA) kits and kit reagents were purchased from R&D Systems
(Minneapolis, MN). Lyophilized gelatin sponges (GelFoam™ sponge sheets) were
purchased from Pfizer (Groton, CT).
4.3.2

Fabrication and characterization of biomaterial system
The outer compartments of these two-compartment biomaterial systems were

made from GelFoam™ gelatin sponges. The 2 x 12 x 7 mm GelFoam™ lyophilized
sheets provided by the manufacturer were shaped into hollow cylinders with biopsy
punches (2 mm thick, 8 mm outer diameter-OD, 4 mm inner diameter-ID). In order to
image the gel’s porous structures, they were sputter-coated with gold for 30 seconds and
imaged under the Scanning Electron Microscopy (SEM) on a Zeiss SIGMA VP Field
Emission-SEM and Energy-dispersive X-ray Spectroscopy (EDS) for elemental mapping.
The inner compartment ferrogels were made of alginate according in a similar
manner to the biphasic ferrogels described elsewhere.21–23 Briefly, alginate (at 1%wt) was
dissolved in MES buffer (100 mM MES and 500 mM NaCl at pH = 6.0) with AAD and
HOBt. This mixture was then mixed with iron Oxide particles (Fe3O4 < 5 μm) and 100
mg/mL EDC. Next, the mixture was cast between two sigmacote-treated glass plates
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separated by 2 mm spacers. During casting (~ 30 minutes), a magnet was placed on top of
the glass plate to pull the iron oxides to the top of the ferrogel, resulting in a biphasic
design. Ferrogels were then cut into 4 x 2 mm (diameter- thickness) disks using 4-mm
biopsy punches. Gels were then washed in deionized water for 3 days with water being
changed 2 to 3 times a day, this was done in order to remove residual reagents and let
them swell. Next, to achieve a porous structure, gels were frozen overnight at -20 °C and
lyophilized. For SEM imaging, ferrogels were cut with a sharp razor, exposing their cross
section and prepped for SEM imaging following the same protocol as described above for
gelatin outer compartments.
4.3.3

Magnetic stimulation of ferrogels
Two different set up were used to magnetically stimulate the Ferrogels, both

involving the use of 0.5”x0.5” cylindrical neodymium magnets (K&J Magnetics,
Pipersville, PA). In one apparatus, magnets were incorporated on a variable-speed
laboratory rocker where magnets were placed on the edges of its platform (4 magnets on
one edge and 4 on the opposite edge). Sigmacote-treated scintillation vials containing
gels were placed on top of these magnets with aluminum clamps and suspended using
standard aluminum laboratory scaffolding. The rocker platform positioned magnets close
(~ 1 mm) to ferrogels contained in the suspended scintillation vials when in the upward
position and positioned the magnets far from the ferrogels when in the downward
position, thus magnetically stimulating the ferrogels in a cyclic manner. The frequency of
the applied magnetic stimulation was thus dependent on the oscillation speed of rocker
with 1.4 Hz being the maximum frequency produced from this apparatus (i.e., magnetic
compression of the ferrogel at a rate of 1.4 Hz under a ~ 5 kGauss magnetic field). While
84

somewhat limited in the frequency of magnetic stimulation, this stimulation apparatus
was capable of continuously stimulating 8 ferrogels simultaneously continuously for
days.
A second apparatus was used for exposing ferrogels to slightly higher frequencies
(up to 14 Hz) but for relatively short periods of time (see Emi et al. for a more thorough
description23). This second setup consisted of a crankshaft driven by a programmable
electric motor. The crankshaft was connected via cams to four pistons (much like a car
engine) that would move up and down in a sinusoidal manner as the crankshaft was
turned by the electric motor. Each piston contained a neodymium magnet and a
scintillation vial containing a ferrogel could be suspended directly above each of the four
pistons. Thus, when the piston was in the up position, a ferrogel would be exposed to a
strong magnetic field (measured to be 5 kGauss). When the piston was in the down
position, the magnetic field was weak (measured to be < 10 Gauss). Thus, the speed of
the motor dictated the magnetic stimulation frequency. It was determined that this
apparatus could magnetically stimulate ferrogels at frequencies up to 14 Hz.
4.3.4

Protein release studies
In order to load proteins to these gels, concentrated solutions of proteins in PBS

were made. It was determined that each outer gelatin compartment had the capacity to
absorb 40 ml of solution which was used as the basis to calculate protein loading
concentrations (i.e., loading of 1000 ng protein would require preparation of a solution
containing 1000 ng GM-CSF in 40 ml PBS). Sigmacote-treated scintillation vials (to
prevent protein adsorption to the surface of the vials) were used as containers for these
gels. Protein carrying solutions were added dropwise to these outer compartments for
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loading. Vials were capped, and gels were left at room temperature overnight for full
absorption of the protein into the gels. Release studies began the next day when gels were
submerged in PBS with 1% BSA (t = 0). 1 ml samples were collected periodically and
replaced with fresh media each time. Collected samples were stored in 1.5 ml lowadsorption tubes in the freezer. After collecting all samples, samples were thawed and
quantified for protein content (i.e., GM-CSF, VEGF, SDF-1α) using ELISA.
Inner compartment fabrication resulted in lyophilized alginate biphasic gels with a
layer of iron-oxide-free porous alginate on one side of the gel and an iron-oxide saturated
layer with smaller pores on the other side of the gel. The loading of these ferrogels and
release studies from them were similar to those described for the outer gelatin
compartments above. However, the absorption capacity of these ferrogels were 20 ml.
Ferrogels were placed in scintillation vials with their iron-oxide free region facing up.
Next, a 20 ml solution containing protein was added to them dropwise. Vials were capped
and left in order for gels to absorb the proteins overnight. Ferrogels were flipped over so
that their iron-oxide-saturated regions faced upwards (so that a magnet applied under the
vial would deform the ferrogel in a downward motion) and then rinsed in PBS with 1%
BSA for between 1 to 4 days to remove proteins that were not well integrated in the gel
structure. Samples were then taken at different times and fresh media was replaced at
each time point. During these time course release experiments, ferrogels were
magnetically stimulated at a number of time points and at various frequencies, depending
on the experiment. ELISA was performed on the collected samples to quantify the
concentration of the released proteins from ferrogels (HSP27, PDGF, BMP2).
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4.3.5

Data representation and statistical analysis
Analysis of variance (ANOVA) with post-hoc Tukey HSD (Honestly Significant

Difference) test was performed in order to determine statistically significant differences
when multiple conditions and comparison were made. The numerical values presented in
the graphs were represent means ± standard deviations from 4 independent replicates (N
= 4). P-values less than 0.05 were considered significant.

4.4

Results

4.4.1

Characterization of the two-compartment biomaterial system
The two-compartment biomaterial system was made of an outer gelatin

compartment and an inner biphasic ferrogel nested within the outer gelatin compartment
(Fig 3. A). The gelatin outer compartment was highly porous (Figure 3. B), which would
be desirable for allowing fast diffusive release of load proteins (due to high surface area)
and potentially efficient penetration of recruited cells. Additionally, by virtue of being
made from gelatin, this outer compartment contained cell-binding integrins needed to
have recruited cells attach the scaffold and proliferate within the scaffold. The inner
biphasic ferrogel compartment contained a Fe3O4 saturated region on the one side of the
gel and a highly porous Fe3O4-free region on the opposite side of the gel (Fig 3. C. i).
This biphasic structure was capable of deforming in the presence of magnetic field (Fig 3.
C. ii).
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Figure 0.3. Dual Compartment biomaterial system with porous outer compartment and
magnetically responsive inner compartment. A) Photographs of the whole system B)
Characterization of the outer compartment with SEM imaging. C) i. SEM with elemental
mapping (bottom) differentiates between Iron (yellow) and carbon (blue) parts of the gel. ii.
Ferrogels before (top) and after (bottom) stimulating with magnet.

4.4.2

Release characteristics of the outer gelatin scaffold
The outer compartment’s porous gelatin scaffold was capable of initially releasing

proteins (proteins described herein as “Factor I”) in a rapid manner. Specifically, DC
recruitment factor (GM-CSF) released mostly within the first 24 hours (Figure 4. A). The
total amount of GM-CSF release was dependent on the amount loaded in the outer
compartment (Figure, 4. A: higher loadings resulted in higher amounts of cumulative
release). This rapid and adjustable initial release of DC recruitment factor may be useful
in rapidly recruiting DCs to the scaffold for biomaterials-based cancer immunotherapy
applications. Similarly, pro-angiogenic factors (VEGF) rapidly released from the gelatin
scaffold, depleting from the gel within the first 12 hours (Figure 4. B). VEGF cumulative
release was also dependent on the amount loaded into the scaffold (Figure 4. B: higher
loadings plateaued at higher levels of cumulative release). This rapidly release of VEGF
may be useful in rapidly initiating vascular sprouting into the scaffold in applications that
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demand neo-vascularization (e.g., treating CVDs, wound healing and tissue engineering
applications). Finally, bone progenitor recruitment factor (SDF-1a) released in a
relatively rapid manner, plateauing 200 hours (Figure 4. C). Again, the final cumulative
release values were a function of the amount of protein loaded (Figure 4. C: higher
loadings yielded higher plateau values). This relatively rapid release profile may enable
rapid recruitment of bone progenitor cells to the scaffold for bone regeneration
applications.
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Figure 0.4. The outer compartment can rapidly release initial factors pertinent to cancer
immunotherapy, tissue vascularization, and bone regeneration. A) Cumulative release versus time
of GM-CSF, B) VEGF, and C) SDF-1α from outer compartment when loaded with different
amounts of proteins (Colors represent different protein concentrations).

4.4.3

Release characteristics of the inner ferrogel
The inner compartment provides magnetically triggered, delayed, and on-demand

release of proteins that can be used to direct the behavior of (i.e., program) cells recruited
to the outer compartment. For example, a model cancer antigen’s (HSP27’s) release rate
drastically increase when ferrogels inner compartments are magnetically stimulated on
days 4 (Figure 5. A, slope of blue curve increases in the blue shaded region of the curve)
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or on day 7 (slope of red curve increases in the red shaded region), depending on when
the magnetic stimulation is applied (i.e., on day 4 or 7, respectively). Note that the
magnetic stimulation used in these studies was at constant 1.4 Hz for 4 hours using the
rocker. These on-demand, delayed enhancements in release rate could be used to
optimize the timepoint at which recruited DCs are earnestly presented with cancer
antigen for biomaterials-based cancer immunotherapy applications.
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Figure 0.5. Timing of the delivery from ferrogels can be controlled by stimulating at different
time points. A) Cumulative release of HSP27 when stimulated on days 4 (blue) and 7 (red). B)
PDGF on days 1 (blue), 4 (red), 8 (green), and C) BMP2 on days 7 (blue).

Likewise, the rate of pro-vascular-maturation factor (PDGF) release could be
greatly enhanced when these ferrogel inner compartments were magnetically stimulated
(Figure 5. B). And again, the time at which magnetic stimulation was applied enabled this
enhanced release to occur at specific times (Figure 5. B: magnetic stimulation on days 1
(blue), 4 (red), or 8 (green) yielded enhancements in release rates on days 1, 4, or 8,
respectively). These magnetically triggered delays in pro-vascular-maturation factors
could help optimize the time allotted for inducing vascular sprouting before re-stabilizing
the nascent vascular network.
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Finally, the rate of osteo-differentiation factor (BMP2) release could also be
enhanced when these ferrogels were magnetically stimulated (Figure 5. C: increased
slope of the blue curve in the blue shaded region). Though the specific timing of this
magnetically triggered enhancement in release rate was not demonstrated as was with
PEGF and HSP27, it is likely that enhancements in release would be generated at
different time points upon magnetic stimulation at different time points. The ability to
magnetically trigger enhancements in osteo-differentiation factors to recruited bone
progenitors may allow for optimizations in how much time is provided to build bone
progenitor populations in the scaffold prior to instructing them to differentiate.
4.4.4

Strategies for magnetically controlling the rate of delayed release
While the delayed release capabilities outlined above may be of use in improving

the timing of deliveries in cancer immunotherapies, re-vascularization therapies, and
bone regeneration, the rate of release when magnetically stimulated is also a critical
parameter for optimization. Here, strategies were explored for using alterations in the
magnetic stimulation profile to regulate the release rate during magnetic stimulation. A
previous study demonstrated that periodically turning on and off sinusoidal magnetic
stimulations could actually improve triggered release rates compared to continuous
sinusoidal magnetic stimulation.24 Here, this principle was investigated further by
adjusting parameters associated with pulsing the magnetic stimulation regiment. Namely,
ferrogel inner compartments were exposed to pulsed magnetic stimulation regiments
where the frequency and duration of magnetic stimulation pulses were changed vs. time.
It was demonstrated that applying different pulsed magnetic stimulation regiments
could be used to control the rate of protein release during magnetic stimulation. For
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example, after 3 days of diffusive release, ferrogels containing HSP27 were magnetically
stimulated using one of two different pulsed regiments: either a regiment switching
between (i) 10 minutes of magnetic stimulation at 5 Hz followed by 50 minutes at 1 Hz,
repeated over 4 hours (Figure 6.A.i: Mag-a), or (ii) 10 minutes stimulation at 10 Hz
followed by 20 minutes at 2 Hz, repeated over 4 hours (Figure 6. A.i: Mag-b). These two
pulsed stimulation profiles resulted in statistically higher release rates on day 3 compared
to controls (Figure 6. A. ii and iii). While these two pulsed stimulation profiles produced
slightly different stimulated release rates on day 3 from each other, there was no
statistically significant difference between them (Figure 6. A. iii: comparing Mag-a to
Mag-b release rates). Statistical differences may be achieved in future studies by finetuning the material makeup of the ferrogel as well and the magnetic stimulation profile
(e.g., different frequencies at different times for different durations and different
magnetic field intensities).
The use of different pulsed magnetic stimulation regiments was more effective in
regulating the rate of PDGF release. For example, PDGF-loaded inner compartment
ferrogels were magnetically stimulated on day 3 using either a pulsed regiment that
switched between (i) 10 minutes of magnetic stimulation at 5 Hz followed by 50 minutes
at 1 Hz, repeated over 4 hours (Figure 6.B.i: Mag-a), or (ii) 30 minutes stimulation at 5
Hz followed by 30 minutes at 10 Hz, repeated over 4 hours (Figure 6. B.i: Mag-b).
Results indicated that both pulsed stimulation profiles enhanced PDGF release rates on
day 3 compared to controls (Figure 6.B. ii and iii). Additionally, one magnetic
stimulation profile enhanced release rates compared to the other stimulation profile
(Figure 6.B. iii: Mag-a is statistically higher than Mag-b).
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Based on the differences in magnetically stimulated release rates between HSP27
and BMP2, it is apparent that different proteins have different stimulated release
characteristics and that these differences are likely influenced by the interactions between
the proteins and the ferrogel’s alginate matrices. For example, BMP2 interacts highly
with alginate (i.e., BMP2 is heparin-binding and alginate is heparin-mimicking). In fact,
when loaded with BMP2, these inner compartment ferrogels had difficulty in releasing
BMP2 at rates that were statistically different than controls. For instance, when loaded
with BMP2 and stimulated on day 3 using either a pulsed regiment that switched between
(i) 10 minutes of magnetic stimulation at 5 Hz followed by 50 minutes at 1 Hz, repeated
over 4 hours (Figure 6.C.i: Mag-a), or (ii) 10 minutes stimulation at 14 Hz followed by
20 minutes at 2 Hz, repeated over 4 hours (Figure 6. c.i: Mag-b), the were no observed
differences in BMP2 release rates compared to controls (Figure 6.C. ii and iii). Again,
however, it may be possible in future studies to demonstrate magnetically triggered
releases rates that are statistically higher than controls when optimizing the material
makeup of the ferrogel and the magnetic stimulation profile (e.g., different frequencies at
different times for different durations and different magnetic field intensities).
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Figure 0.6. Rate of the delivery of proteins from ferrogels can be controlled by applying various
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4.5

Discussion
These two-compartment biomaterial systems may provide improvements in a

wide range of biomedical applications, including biomaterial-based cancer
immunotherapies, therapies involving regeneration of vascular networks, and in bone
regeneration. For example, the sequential deliveries of DC recruitment factors followed
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by flexibly timed and delayed delivery of cancer antigen may enable specific
improvements in biomaterial-based cancer immunotherapies. While biomaterial-based
cancer immunotherapy has shown promising results (90% mouse survival after 3 months
after being challenged with xerographic melanoma if biomaterial cancer vaccines were
implanted 14 days prior to cancer challenge),25 when the biomaterial vaccine was
implanted in mice with existing melanomas (well-developed 13-day-old tumors) mouse
survival rates were less promising.26 A potential area of improvement for these strategies
lies in the timing of DC recruitment and the presentation of cancer antigen to recruited
DCs. In the biomaterial melanoma vaccine described above,25,26 DCs are presented with
activation factors (cancer antigen and danger signal) as they enter the scaffold. This may
result in (i) diffusive loss of activation factors while DCs are in transient during
recruitment and (ii) activation of DCs being distributed over time (i.e., not all DCs arrive
in the scaffold and are presented with activation factors at the same time). Both of these
may result in a less intense anti-tumor response from the host. The two-compartment
magnetically responsive biomaterial system presented could enable recruitment of DCs to
the outer compartment and then delivery of activation factors to recruited DCs only after
a strong population of DCs has been recruited to the scaffold. In this manner, a strong
population of DCs can be activated, enabling a high number of activated DCs to home to
the lymph nodes, initiating a potent anti-cancer immunogenic response. Moreover, the
biomaterial system described here could enable (i) optimizations in regard to the timing
of recruited DC activation and (ii) could provide repeated/subsequent release of
activation factors through subsequent magnetic stimulations (i.e., injection-less boosters).
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The biomaterial system described here may also provide improvements for therapies
where new vasculature needs to be developed. Due to the biology outlined in Fig 1.B,
sequential release of pro-angiogenic (VEGF) and pro-maturation (PDGF) factors is
necessary for growth of new vasculature. In light of this, Richardson et al.27 created a
biomaterial capable of delivering both VEGF and PDGF, ostensibly in sequence, by
composing a scaffold with different degradation rates. While delivery of PDGF alone
improved vessel maturation (as measured by the distribution in vessel diameter)
compared to VEGF delivery alone, combined release of VEGF + PDGF did not improve
average vessel diameter with statistical significance over PDGF delivery alone. This may
have been due to the specific temporal profiles of VEGF and PDGF delivery from the
system. The differential degradation approach adopted by Richardson et al. yielded
VEGF and PDGF release profiles that were more of different rates as opposed to
sequential per se. That is, there was not a drastic (albeit slight) increase in PDGF release
at later time points (i.e., dramatically delayed PDGF increases in release rate, as observed
here in using magnetically responsive ferrogels). This lack of sequential delivery may
have not property coordinated the sequence of pericyte detachment, vascular sprouting,
vascular invasion, pericyte re-recruitment and attachment, and sprout maturation required
to generate mature vasculature. The delivery profiles achieved by the two-compartment
biomaterial system described here may more properly coordinate these sequential
biological events. Furthermore, the on-demand capabilities of this two-compartment
system may enable critical optimization in the timing allowed for sprouting and sprout
infiltration prior to initiating vascular maturation.
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Finally, the two-compartment magnetically responsive biomaterial system
described here might be beneficial for optimizing deliveries in treating bone defects,
injuries, and diseases. Regenerating bone requires coordinated sequence recruitment,
proliferation, and differentiation events, which can each potentially be coordinated
through protein deliveries. In an attempt to coordinate these events, Lee et al.28 developed
a biomaterial that contained two factors with the goal of enhancing the number of
calcium phosphate matrix-producing osteoblasts: TGFβ (to enhance the population of
bone progenitors resident in the regenerative scaffold) and BMP2 (to differentiate those
bone progenitors into osteoblasts). While this strategy demonstrated that BMP2-loaded
scaffolds yielded significantly higher amounts of bone-matrix than controls, dual-loaded
BMP2/TGFβ scaffolds did not produce more bone matrix than only BMP2-loaded
scaffolds (and may in fact have yielded less bone matrix). Again, this result may have
been due to the timing of how and when these proteins were presented to bone
progenitors as they entered the scaffold from surrounding tissues. For example, while
TGFβ is known to enhance cell proliferation, it is also known that differentiated cells do
not proliferate well.28 Thus, if cells are instructed to osteo-differentiate by being
presented with BMP-2 upon entering the scaffold, they may not proliferate well despite
receiving instruction to proliferate through TGFβ presentation. This set of simultaneous
and conflicting instructions may have limited the number of osteo-differentiate cells in
the Lee et al. studies. However, if presented in sequence (i.e., first to proliferate to a
strong population while retaining their stem-like ability to proliferate through TGFβ
signaling; and then to differentiate down the osteogenic lineage through BMP2
signaling), it may be possible to generate a more robust population of bone-matrix-
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producing osteoblasts. The dual-compartment material system presented here may afford
coordination of this sequence and furthermore be capable of optimizing the timing of this
sequence for maximized bone matrix production.

4.6

Conclusions
In this study, a biomaterial system was developed and its ability to sequentially

release two different proteins pertinent to three therapies was demonstrated. This system
was capable of rapidly releasing initial factors (GM-CSF, VEGF, or SDF-1a) from a
porous gelatin outer compartment that was designed to facilitate cell infiltration. The
amount of this delivery depended on the amount of the factor that was loaded into the
outer compartment. Additionally, this biomaterial system contained a magnetically
responsive ferrogel inner compartment, which was able to produce enhanced delivery of
its payload (HSP27, PDGF, or BMP2) at a time dictated by an externally applied
magnetic signal. It was also demonstrated that the rates of these delayed and magnetically
triggered protein deliveries could potential be regulated by altering the frequencies and/or
temporal profile of the magnetic stimulation itself.
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Chapter 5

Summary and Prospective Research
5.1

Primary goals
The research described in this dissertation was to investigate magnetically

responsive drug delivery systems and develop a biomaterial system capable of controlling
the rate and timing of different biomolecular deliveries in response to a remotely applied
magnetic fields. More specifically, this doctoral research aimed to (1) develop a dual
compartment biomaterial system capable of generating sequences of biomolecular
deliveries in response to low-frequency, spatially graded magnetic fields, and (2) to
investigate the applications of this developed biomaterial for delivering critical
biomolecules in several therapeutic applications that may be enhanced through sequential
deliveries.

5.2

Summary of individual chapters
While Chapter 1 broadly motivated the work that is contained in this dissertation,

Chapter 2 elaborated on this motivation by discussing existing hydrogel-based
magnetically responsive biomaterials with some highlighted examples and in terms of
mechanisms of magnetically triggered release and parameters that influence release
characteristics.

A few case studies were examined where magnetically responsive
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hydrogels were used to generate temporally complex and multi-drug delivery profiles.
However, Chapter 2 in fact underscored how not many magnetically responsive
biomaterials had been introduced that demonstrated the capability of regulating
temporally complex, multi-drug deliveries. This underscores the urgency for novel
biomaterial systems with these capabilities. Thus, in Chapters 3 and 4, a novel
biomaterial system was described that was specifically designed to generate temporally
complex, multi-drug delivery profiles in response to remotely applied magnetic stimuli.
Chapter 3 focused on developing and demonstrating novel delivery capabilities
for a biomaterial system possibly capable of regulating the inflammation response in
wound healing applications. This two-compartment biomaterial system was designed to
initially release factors that could recruit a population of pro-inflammatory macrophages
(i.e., by delivering MCP-1 and IFNg from an outer compartment that was porous and
presented integrins for macrophage binding). Magnetically triggered release of antiinflammatory factors (i.e., IL4 and/or IL10 from a magnetically deformable ferrogel as
the inner compartment) was designed to switch off the inflammation and the promote
healing processes.
Chapter 4 explored the use of this two-compartment biomaterial system in
additional applications where remote regulation of the timing of sequential biomolecular
deliveries may be of high clinical value. Specifically, the dual compartment biomaterial
system was loaded with biomolecules pertinent to cancer immunotherapy, tissue
vascularization, and bone regeneration. Biological processes relevant to these three
applications can each benefit sequential regulation of biosocial events through sequenced
biomolecular deliveries.

For instance, in biomaterial-based cancer immunotherapy
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applications, a goal for potentially improving these therapies is to increase the number of
the activated dendritic cells. This possibly can be done by releasing DC recruitment
factor while holding on to the activating factor inside the ferrogel and have it be released
to recruited DCs only when the DC population is relatively high. This would lead to
increased numbers of activated immune cells and a stronger anti-cancer immune
response. Indeed, the two-compartment biomaterial system developed was demonstrated
to sequentially deliver DC recruitment factors (i.e., GM-CSF) followed by magnetically
triggered delivery of DC activation factors (i.e., single stranded DNA and a model protein
antigen, HSP-27). In tissue vascularization applications, the aim was to demonstrate
sequential deliveries that could direct the sprouting of immature vascular sprouts,
followed by coordination of events that lead to maturation of those vascular sprouts.
Indeed, the two-compartment biomaterial system was demonstrated to sequentially
deliver pro-angiogenic sprouting factors (i.e., VEGF) followed by magnetically triggered
pro-maturation factors (i.e., PDGF). In bone regeneration applications, the aim was to
demonstrate sequential deliveries that could first recruit bone progenitor cells followed
by differentiation of those recruited progenitor cells down the osteogenic lineage. Again,
this work successfully demonstrated the ability to first release a bone progenitor
recruitment factor (SDF-1a) followed by magnetically triggered release of an osteodifferentiation factor (BMP-2).

5.3

Impact and importance of this work
The biomaterial system developed and demonstrate in this dissertation can

potentially be used to help scientists better understand how the dosing, sequence, and
timing of the drug release can impact the outcome in wound healing, cancer
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immunotherapies, and tissue engineering (i.e., neo-vascularization of and establishing
populations of tissue-specific cell types within defect sites). This can help scientists
optimize different drug delivery regiments before moving on to clinical trials and
implementing the dosing on patients. Also, the on-demand nature of these magnetically
responsive materials will help enable rapid optimizations since the material itself does not
need to be altered between experiments (i.e., the same material system is capable of
producing a wide variety of delivery profiles whereas a traditional biomaterial must be
reformulated to produce different delivery profiles). Furthermore, the on-demand nature
of these magnetically responsive biomaterials would enable real-time alterations in
delivery schedules, which would provide a high degree of flexibility for clinicians to alter
the course of therapy in real time according to updates in patient prognosis. Finally, from
a practical standpoint, the magnetic stimulations needed for these triggered deliveries
involve benign fields from simple, inexpensive, hand-held magnets.
Another significant aspect of this project involves the fact that this developed
drug delivery system can be made with variety of biomaterials in different shapes and
sizes and can be loaded with many different bioactive molecules, depending on the
desired application. For example, the porosity of the outer compartment can be adjusted
for controlling the diffusion rate of the drug as well as the chemistry of the polymer
which can be easily modified to attach different molecules to it. Also, these biomaterials
can be designed to degrade in body within a desired timeframe, which holds up the need
to take out the biomaterial once it is no longer required. This is particularly desirable in
tissue engineering applications where the body will replace the scaffold with its own
native extracellular matrix.
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5.4

Future directions
While some very critical developments, characterizations, and demonstrations

were performed in this dissertation, the biomaterial system developed here needs to be
further examined in vitro and in vivo in order to truly uncover its ability to
therapeutically regulate key biological processes. For example, for demonstrating the use
of the dual compartment system in controlling macrophage phenotype change vs. time in
vitro, RAW 264.7 (ATCC(R) TIB-71™) could be seeded in 12 well plates. The dual
compartment biomaterial system would be loaded with factors so that M1 (inflammatory)
macrophages would be rapidly recruited to the outer compartment. Factors that could
transition those M1 macrophages into pro-healing (anti-inflammatory) M2 macrophages
would be loaded in the inner compartment (where they would remain until magnetically
triggered to release). This loaded biomaterial would be placed on top of the seeded
macrophages and they would be allowed to infiltrate the outer compartment where they
would establish a population of M1 macrophages. Over the course of several days, the
biomaterial could be magnetically stimulated at different times, releasing antiinflammatory factors (IL4 and/or IL10) to trigger an anti-inflammatory response in the
macrophages (i.e., transition them from M1 to M2 phenotypes) at different times. The
phenotype of macrophages resident in the biomaterial can be quantified vs. time by using
common antibody staining (anti-mouse CCR7 for M1 macrophages and anti-mouse
CD206 for M2) or by measuring the proteins secreted by macrophages (VEGF for M1
macrophages and PDGF for M2 macrophages). In this manner, the biomaterials system’s
ability to regulate macrophage phenotype vs. time can be tested/verified.

108

For testing its application in cancer immunotherapy, JAWSII (ATCC® CRL11904™) that are immature dendritic cells (DCs) could be seeded in 12 well plates.
Biomaterial system can be loaded with DC recruitment factor in the outer compartment
and DC activating factor in the inner ferrogel. The dual compartment system then can be
placed on top of the seeded dendritic cells. With release of the recruitment factor from the
outer compartment (GM-CSF), DC cells will populate the gelatin part of the system, after
few days ferrogel can be triggered to release activating factors such as cancer antigen
(i.e., Heat shock protein 27 (HSP27) or danger signal, single stranded nucleic acid
(ssNA)). Activation of the dendritic cells can be validated by antibody staining the cells
for both “anti-mouse CCR7” and “anti-mouse MHCII” marker on the cells. We can
collect the histogram for stained cells using Nexcelom cellometer. Also cell studies need
to be done in regulating sprouting and pericyte/endothelial cell co-localization in vascular
models. A co-culture of independently stained endothelial cells (red) and pericytes (blue)
is required. In order to do that we plan on seeding the Human dermal microvascular
endothelial cells (HMVECs) that are stained with octadecyl rhodamine B chloride, (R18,
Molecular Probes O-246-blue) along with Pericytes stained with CMFDA (red). These
two cell lines will be co-cultured on a fibrin laden 6-well plate. Biomaterial system will
be placed on top of the culture with media. Diffusive release of VEGF from the gelatin
triggers pericyte detachment and forming of the vessel sprouts. The stimulated PDGF
release helps pericyte attachment and initiates vessel maturation. The number of vessel
sprouts and number of attached and detached pericytes will be manually counted using
confocal microscopy technique. Moreover, for in vitro model in improving osetodifferentiation in bone regeneration, mesenchymal stem cells (MSCs) can be seeded in
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well plates. Dual compartment system loaded with stromal cell derived factor 1 (SDF-1α)
in outer section for recruiting MSCs and bone morphogenetic protein-2 (BMP-2) loaded
inner ferrogel can be placed on top of the cells. After stem cell recruitment to the
biomaterial, stimulated release of BMP-2 from the ferrogel will differentiate the MSCs to
bone lineage. For counting the recruited cells, we can fix and stain the gel holding the
cells with DAPI for cell nuclei and Phalloidin to stain the F-actin and images were taken
using confocal microscope. For osteo-differentiation, the culture media can be collected
on daily basis and analyzed using ELISA for “osteocalcin” secretion as indicator of early
stage osteo-differentiation and for “Alizarin Red” to stain calcium phosphate as an
indicator of late stage osteo-differentiation.
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Appendix A
Supporting Information
for Adv. Healthcare Mater., DOI: 10.1002/adhm.201300260
A Magnetically Responsive Biomaterial System for Flexibly
Regulating the Duration Between Pro- and Anti-Inflammatory Cytokine
Deliveries
By Anita E. Tolouei, Nihan Dülger, Rosa Ghatee, Stephen Kennedy*

Materials: Sodium alginate was donated from Pronova Biopolymers (Oslo,
Norway) with an average molecular weight of ~250 kDa and with high guluronate
content

(Protoanal

LF

20/40).

Adipic

acid

dihydrazide

(AAD),

1-ethyl-3-

(dimethylaminopropyl) carbodiimide (EDC), MES, 1-hydroxybenzotriazole (HOBT),
iron (II,III) oxide powder (< 5 micron), Phosphate Buffered Saline (PBS), Sigmacote®,
bovine serum albumin (BSA), paraformaldehyde (PFA), Triton X-100, fluorescein
isothiocyanate

(FITC)

labeled

phalloidin,

and

2-(4-Amidinophenryl)-6-

indolecarbamidine dihydrochloride (DAPI) were all purchased from Sigma-Aldrich (St.
Louis, MO). Mouse Monocyte Chemoattractant Protein-1 (MCP-1), Interferon Gamma
(IFN-γ),

Interleukin-4

(IL-4),

Interleukin-10

(IL-10),

and

all

Enzyme-linked

Immunosorbent Assay (ELISA) kits and kit reagents were purchased from R&D Systems
(Minneapolis, MN).
Macrophage culturing: RAW 264.7 mouse macrophages (ATCC, Manassas, VA)
were used in these studies. Macrophages were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM, Sigma) containing 10% fetal bovine serum (FBS, Sigma) and 1%
penicillin-streptomycin (Sigma) in 75 cm2 flasks at 37ºC and 5% CO2 and split every 2-3
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days at a 1:3 to 1:6 ratio, as recommended by the manufacturer.
Mechanical characterization of biphasic ferrogels before and after magnetic
stimulation: Biphasic ferrogel (inner compartments) stiffness (Young’s modulus) before
and after magnetic stimulation was quantitatively measured in compression using an
Instron Model 3345 (Norwood, MA). Prior to magnetic stimulation, biphasic ferrogels
were placed between the plates of the Instron and compressed (at 2 mm/min) until
reaching 50% strain in order to produce a well-define elastic region on the stress-strain
curve. Note that this compression resulted in deformation of only the iron-oxide-free
region of the ferrogels and not the much stiffer/denser iron-oxide-laden region. Recorded
stress-strain curves were analyzed using the Instron’s Bluehill software package to
extract moduli. Because this compression test could have damaged the gels, separate sets
of gels were magnetically stimulated and mechanically tested after being exposed to
magnetic stimulation profiles.
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Figure 0.1. S1. Outer porous gelatin scaffolds rapidly released MCP-1 and IFN-γ in the first 12
hours. (a) Cumulative MCP-1 release during the first 12-hours of experimentation for gelatin
scaffolds loaded with 1000 ng (solid red) and 100 ng (dashed red) MCP-1. (b) Cumulative IFN-γ
release during the first 12-hours of experimentation for gelatin scaffolds loaded with 1000 ng
(solid red) and 100 ng (dashed red) IFN-γ. Inset: zoom-in of cumulative release for 100 ng-loaded
scaffolds. For parts (a) and (b), N = 4.
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Figure 0.2. S2. Ferrogel mechanics did not significantly change due to magnetic stimulation. (a)
Schematics of the two stimulation profiles used: continuous stimulation at 1.4 Hz for 3 hours
(top) and periodic stimulation at 1.4 Hz for 5 min every hour on the hour for 3 hours. (b) Young’s
modulus of ferrogels before stimulation (black), after stimulation profile A (green), and after
stimulation profile B (red). N = 4.
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<< MovieS1.avi >>
Movie S1. 3D z-stack reconstruction of macrophages recruited to the bottom 170
μm of a porous gelatin scaffold. Scaffold and macrophages were stained to identify factin (green) and cell nuclei (blue).

<< MovieS2.mov >>
Movie S2. Biphasic ferrogel being cyclically compressed at 1.4 Hz using a
magnet on our custom rocker setup.
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